[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8qP-0p7BJ2cp7D-YOfXkkmtOuBi1Q9CcV3anc4tZJq4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Georgetown University",[4],285,false,53,18,71719,40,152,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Breast Cancer",28,{"name":18,"count":19},"Prostate Cancer",8,{"name":21,"count":22},"Stroke",7,{"name":24,"count":22},"Colorectal Cancer",{"name":26,"count":27},"Lung Cancer",6,{"name":29,"count":30},"Pancreatic Cancer",5,{"name":32,"count":30},"Chronic Lymphocytic Leukemia",{"name":34,"count":30},"Metastatic Pancreatic Cancer",[36,41,46,51,56,61,66,71,76,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03996460","K0706 for Patients Diagnosed With Dementia With Lewy Bodies","2023-06","192 mg powder of K0706",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04091750","Nivolumab\u002FIpilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma","2023-08-08","Nivolumab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06227546","MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer","2025-03-28","MGC018",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04005339","NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","2025-09-03","Nanoliposomal Irinotecan",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05558982","BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","2025-12-31","BXCL701",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06248515","A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors","2026-04","Sacituzumab govitecan-hziy",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05551858","Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis","2026-06-30","Proglumide",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT04865887","Pembrolizumab and Lenvatinib in Advanced Cervical Cancer","2026-07","Pembrolizumab",{"nctId":77,"briefTitle":78,"date":74,"intervention":79},"NCT04958811","Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","Tiragolumab",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04990102","Phase IB\u002FII of CPX-351 for Relapse Prevention in AML","2026-12","CPX-351",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,161,184,255,311,365,407,438,460,482,518,540,571,589,607,628,654,672,693,711,731,749,767,787,811,829,847,874,892,915,933,951,975,993,1021,1039,1057,1075,1093,1128,1146,1183,1208,1238,1265,1283,1301,1319,1344,1369,1387,1414,1442,1460,1484,1502,1527,1545,1569,1587,1612,1636,1661,1684,1707,1734,1752,1777,1795,1820,1845,1869,1913,1949,1971,2007,2029,2069,2103,2131,2149,2167,2185,2214,2232,2250,2268,2286,2304,2322,2348,2366,2392,2416,2438,2462,2484,2507,2525,2543,2561,2579,2604,2622,2640,2665,2683,2710,2728,2746,2770,2788,2812,2835,2853,2871,2894,2916,2943,2961,2979,2997,3021,3039,3062,3080,3098,3120,3146,3164,3182,3205,3229,3247,3269,3293,3321,3339,3357,3375,3400,3418,3439,3460,3485,3510,3532,3557,3581,3608,3626,3650,3668,3686,3710,3736,3754,3776,3800,3824,3842,3860,3884,3906,3932,3950,3968,3986,4004,4025,4048,4066,4087,4121,4143,4169,4204,4226,4253,4277,4305,4323,4341,4367,4389,4411,4436,4460,4478,4501,4525,4554,4572,4590,4608,4626,4644,4662,4680],{"intervention":94,"totalTrials":95,"cells":96},"Bevacizumab",4,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":139,"PHASE4":157,"NA":159},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":138,"soonestReadout":74},[104,115,129],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":95,"conditions":111,"interventions":113},"NCT02654639","Ph 2 Study of TAS-102 \u002F Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer","TERMINATED",[88],"2017-11","2016-02",[112],"Metastatic Colorectal Cancer",[114,94],"TAS-102",{"nctId":116,"briefTitle":117,"status":107,"phases":118,"primaryCompletion":119,"completion":120,"start":121,"enrollment":19,"conditions":122,"interventions":125},"NCT03376659","Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma",[87,88],"2021-08-30","2023-08-01","2018-08-08",[112,123,124,34],"Colorectal Adenocarcinoma","Pancreatic Adenocarcinoma",[126,127,128,94],"Durvalumab","CV301","Capecitabine",{"nctId":77,"briefTitle":78,"status":130,"phases":131,"primaryCompletion":74,"completion":83,"start":132,"enrollment":133,"conditions":134,"interventions":136},"ACTIVE_NOT_RECRUITING",[88],"2021-12-21",29,[135],"Non-squamous Non-small-cell Lung Cancer",[79,137,94],"Atezolizumab",1,{"trials":140,"activeCount":138,"soonestReadout":83},[141],{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":83,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":156},"NCT05482516","Evaluating Novel Therapies in ctDNA Positive GI Cancers","RECRUITING",[89],"2028-12","2023-03-29",20,[150,151,152,124,153,154,155],"Colon Adenocarcinoma","Rectal Adenocarcinoma","Gastric Adenocarcinoma","Hepatocellular Carcinoma","Adenocarcinoma of Biliary Tract","Gallbladder Adenocarcinoma",[137,94],{"trials":158,"activeCount":99},[],{"trials":160,"activeCount":99},[],{"intervention":137,"totalTrials":162,"cells":163},2,{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":174,"PHASE4":180,"NA":182},{"trials":165,"activeCount":99},[],{"trials":167,"activeCount":99},[],{"trials":169,"activeCount":138,"soonestReadout":74},[170],{"nctId":77,"briefTitle":78,"status":130,"phases":171,"primaryCompletion":74,"completion":83,"start":132,"enrollment":133,"conditions":172,"interventions":173},[88],[135],[79,137,94],{"trials":175,"activeCount":138,"soonestReadout":83},[176],{"nctId":142,"briefTitle":143,"status":144,"phases":177,"primaryCompletion":83,"completion":146,"start":147,"enrollment":148,"conditions":178,"interventions":179},[89],[150,151,152,124,153,154,155],[137,94],{"trials":181,"activeCount":99},[],{"trials":183,"activeCount":99},[],{"intervention":45,"totalTrials":30,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":187,"activeCount":99},[],{"trials":189,"activeCount":99},[],{"trials":191,"activeCount":162,"soonestReadout":44},[192,205,217,224,237],{"nctId":193,"briefTitle":194,"status":107,"phases":195,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":203},"NCT02978443","A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab",[88],"2020-07-28","2022-08-02","2017-07-26",14,[201,202],"Acral Lentiginous Melanoma","Mucosal Melanoma",[45,204],"Ipilimumab",{"nctId":206,"briefTitle":207,"status":208,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":216},"NCT03487666","OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease","COMPLETED",[88],"2021-11-03","2024-05-02","2018-05-21",45,[215],"Triple Negative Breast Cancer",[45,128],{"nctId":42,"briefTitle":43,"status":130,"phases":218,"primaryCompletion":44,"completion":83,"start":219,"enrollment":199,"conditions":220,"interventions":222},[88],"2020-03-02",[221],"Melanoma",[45,204,223],"Cabozantinib",{"nctId":225,"briefTitle":226,"status":144,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":234},"NCT06015724","Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer",[88],"2027-06","2024-01-31",54,[232,233],"Pancreatic Ductal Adenocarcinoma","Refractory Non-Small Cell Lung Cancer",[235,236,45],"Daratumumab","KRAS vaccine",{"nctId":238,"briefTitle":239,"status":208,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":248},"NCT03325816","Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer",[87,88],"2019-03-28","2020-08-11","2017-11-20",9,[246,247],"Small Cell Lung Cancer","Small Cell Lung Cancer Extensive Stage",[45],{"trials":250,"activeCount":99},[],{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":99},[],{"intervention":75,"totalTrials":95,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":162,"soonestReadout":59},[263,272,280,294],{"nctId":72,"briefTitle":73,"status":144,"phases":264,"primaryCompletion":74,"completion":74,"start":265,"enrollment":266,"conditions":267,"interventions":270},[88],"2022-10-07",35,[268,269],"Cervical Cancer","Metastatic Cervical Cancer",[75,271],"Lenvatinib",{"nctId":57,"briefTitle":58,"status":130,"phases":273,"primaryCompletion":59,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":279},[88],"2027-11","2023-08-16",22,[278],"Metastatic Pancreatic Ductal Adenocarcinoma",[60,75],{"nctId":281,"briefTitle":282,"status":283,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":213,"conditions":288,"interventions":292},"NCT02364076","Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma","UNKNOWN",[88],"2019-06","2021-12","2015-03",[289,290,291],"Thymic Carcinoma","Thymus Neoplasms","Thymus Cancer",[75,293],"Epacadostat",{"nctId":295,"briefTitle":296,"status":208,"phases":297,"primaryCompletion":298,"completion":299,"start":300,"enrollment":199,"conditions":301,"interventions":303},"NCT04306367","Study of Pembrolizumab and Olaparib in Bile Duct Cancer",[88],"2023-07-16","2024-12-19","2020-04-01",[302],"Cholangiocarcinoma",[75,304],"Olaparib",{"trials":306,"activeCount":99},[],{"trials":308,"activeCount":99},[],{"trials":310,"activeCount":99},[],{"intervention":70,"totalTrials":95,"cells":312},{"EARLY_PHASE1":313,"PHASE1":325,"PHASE2":337,"PHASE3":359,"PHASE4":361,"NA":363},{"trials":314,"activeCount":99},[315],{"nctId":316,"briefTitle":317,"status":208,"phases":318,"primaryCompletion":119,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":324},"NCT04814602","Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment",[86],"2022-02-20","2021-03-30",11,[323],"Cirrhosis, Liver",[70],{"trials":326,"activeCount":99},[327],{"nctId":328,"briefTitle":329,"status":208,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":9,"conditions":334,"interventions":336},"NCT04152473","Safety and Tolerability of Oral Proglumide for NASH",[87],"2022-08-31","2022-09-09","2019-12-13",[335],"Nonalcoholic Steatohepatitis",[70],{"trials":338,"activeCount":162,"soonestReadout":69},[339,349],{"nctId":67,"briefTitle":68,"status":130,"phases":340,"primaryCompletion":69,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":348},[87,88],"2026-12-31","2022-11-17",32,[345,346,347],"Safety Issues","Pain","Pancreas Fibrosis",[70],{"nctId":350,"briefTitle":351,"status":130,"phases":352,"primaryCompletion":353,"completion":353,"start":229,"enrollment":354,"conditions":355,"interventions":356},"NCT05827055","Proglumide and Chemotherapy for Metastatic Pancreatic Cancer",[88],"2027-01",30,[34],[357,358,70],"Gemcitabine","Nab paclitaxel",{"trials":360,"activeCount":99},[],{"trials":362,"activeCount":99},[],{"trials":364,"activeCount":99},[],{"intervention":126,"totalTrials":366,"cells":367},3,{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":369,"activeCount":99},[],{"trials":371,"activeCount":99},[],{"trials":373,"activeCount":138,"soonestReadout":378},[374,385,397],{"nctId":375,"briefTitle":376,"status":144,"phases":377,"primaryCompletion":378,"completion":379,"start":380,"enrollment":9,"conditions":381,"interventions":383},"NCT04499053","Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer",[88],"2027-02","2027-12","2020-12-09",[382],"Carcinoma, Non-Small Cell Lung",[126,384],"Tremelimumab",{"nctId":386,"briefTitle":387,"status":388,"phases":389,"primaryCompletion":390,"completion":390,"start":391,"enrollment":99,"conditions":392,"interventions":395},"NCT06017297","Neoadjuvant Tremelimumab and Durvalumab With Gem\u002FCis in Intrahepatic Cholangiocarcinoma","WITHDRAWN",[88],"2026-11","2024-12",[393,394],"Borderline Resectable Carcinoma","Biliary Tract Cancer",[126,384,357,396],"Cisplatin",{"nctId":116,"briefTitle":117,"status":107,"phases":398,"primaryCompletion":119,"completion":120,"start":121,"enrollment":19,"conditions":399,"interventions":400},[87,88],[112,123,124,34],[126,127,128,94],{"trials":402,"activeCount":99},[],{"trials":404,"activeCount":99},[],{"trials":406,"activeCount":99},[],{"intervention":357,"totalTrials":366,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":422,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":410,"activeCount":99},[],{"trials":412,"activeCount":99},[413],{"nctId":414,"briefTitle":415,"status":388,"phases":416,"primaryCompletion":74,"completion":74,"start":417,"enrollment":99,"conditions":418,"interventions":419},"NCT06017323","Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma",[87],"2023-10",[34],[357,358,420,421],"Proglumide Dose level 1","Proglumide Dose level 2",{"trials":423,"activeCount":138,"soonestReadout":353},[424,428],{"nctId":386,"briefTitle":387,"status":388,"phases":425,"primaryCompletion":390,"completion":390,"start":391,"enrollment":99,"conditions":426,"interventions":427},[88],[393,394],[126,384,357,396],{"nctId":350,"briefTitle":351,"status":130,"phases":429,"primaryCompletion":353,"completion":353,"start":229,"enrollment":354,"conditions":430,"interventions":431},[88],[34],[357,358,70],{"trials":433,"activeCount":99},[],{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":99},[],{"intervention":384,"totalTrials":162,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":441,"activeCount":99},[],{"trials":443,"activeCount":99},[],{"trials":445,"activeCount":138,"soonestReadout":378},[446,450],{"nctId":375,"briefTitle":376,"status":144,"phases":447,"primaryCompletion":378,"completion":379,"start":380,"enrollment":9,"conditions":448,"interventions":449},[88],[382],[126,384],{"nctId":386,"briefTitle":387,"status":388,"phases":451,"primaryCompletion":390,"completion":390,"start":391,"enrollment":99,"conditions":452,"interventions":453},[88],[393,394],[126,384,357,396],{"trials":455,"activeCount":99},[],{"trials":457,"activeCount":99},[],{"trials":459,"activeCount":99},[],{"intervention":204,"totalTrials":162,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":463,"activeCount":99},[],{"trials":465,"activeCount":99},[],{"trials":467,"activeCount":138,"soonestReadout":44},[468,472],{"nctId":193,"briefTitle":194,"status":107,"phases":469,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":470,"interventions":471},[88],[201,202],[45,204],{"nctId":42,"briefTitle":43,"status":130,"phases":473,"primaryCompletion":44,"completion":83,"start":219,"enrollment":199,"conditions":474,"interventions":475},[88],[221],[45,204,223],{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":99},[],{"intervention":483,"totalTrials":162,"cells":484},"Rituximab",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":512,"PHASE4":514,"NA":516},{"trials":486,"activeCount":99},[],{"trials":488,"activeCount":99},[],{"trials":490,"activeCount":138,"soonestReadout":83},[491,502],{"nctId":492,"briefTitle":493,"status":208,"phases":494,"primaryCompletion":495,"completion":496,"start":497,"enrollment":276,"conditions":498,"interventions":499},"NCT00860457","Lenalidomide Following Fludarabine\u002FRituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)",[88],"2011-03","2012-02","2008-02",[32],[483,500,501],"Fludarabine","Lenalidomide",{"nctId":503,"briefTitle":504,"status":130,"phases":505,"primaryCompletion":83,"completion":83,"start":506,"enrollment":507,"conditions":508,"interventions":509},"NCT03467867","A Study of Venetoclax and Rituximab\u002FHyaluronidase Human in Relapsed\u002FRefractory CLL",[88],"2018-04-26",25,[32],[510,483,511],"Venetoclax","Rituximab\u002FHyaluronidase Human",{"trials":513,"activeCount":99},[],{"trials":515,"activeCount":99},[],{"trials":517,"activeCount":99},[],{"intervention":358,"totalTrials":162,"cells":519},{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":528,"PHASE3":534,"PHASE4":536,"NA":538},{"trials":521,"activeCount":99},[],{"trials":523,"activeCount":99},[524],{"nctId":414,"briefTitle":415,"status":388,"phases":525,"primaryCompletion":74,"completion":74,"start":417,"enrollment":99,"conditions":526,"interventions":527},[87],[34],[357,358,420,421],{"trials":529,"activeCount":138,"soonestReadout":353},[530],{"nctId":350,"briefTitle":351,"status":130,"phases":531,"primaryCompletion":353,"completion":353,"start":229,"enrollment":354,"conditions":532,"interventions":533},[88],[34],[357,358,70],{"trials":535,"activeCount":99},[],{"trials":537,"activeCount":99},[],{"trials":539,"activeCount":99},[],{"intervention":510,"totalTrials":162,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":565,"PHASE4":567,"NA":569},{"trials":543,"activeCount":99},[],{"trials":545,"activeCount":99},[],{"trials":547,"activeCount":138,"soonestReadout":83},[548,561],{"nctId":549,"briefTitle":550,"status":208,"phases":551,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":559},"NCT02956382","Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma",[87,88],"2023-05-23","2024-03-07","2017-03-01",24,[557,558],"Refractory Follicular Lymphoma","Relapsed Follicular Lymphoma",[560,510],"Ibrutinib",{"nctId":503,"briefTitle":504,"status":130,"phases":562,"primaryCompletion":83,"completion":83,"start":506,"enrollment":507,"conditions":563,"interventions":564},[88],[32],[510,483,511],{"trials":566,"activeCount":99},[],{"trials":568,"activeCount":99},[],{"trials":570,"activeCount":99},[],{"intervention":271,"totalTrials":138,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":574,"activeCount":99},[],{"trials":576,"activeCount":99},[],{"trials":578,"activeCount":138,"soonestReadout":74},[579],{"nctId":72,"briefTitle":73,"status":144,"phases":580,"primaryCompletion":74,"completion":74,"start":265,"enrollment":266,"conditions":581,"interventions":582},[88],[268,269],[75,271],{"trials":584,"activeCount":99},[],{"trials":586,"activeCount":99},[],{"trials":588,"activeCount":99},[],{"intervention":60,"totalTrials":138,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":592,"activeCount":99},[],{"trials":594,"activeCount":99},[],{"trials":596,"activeCount":138,"soonestReadout":59},[597],{"nctId":57,"briefTitle":58,"status":130,"phases":598,"primaryCompletion":59,"completion":274,"start":275,"enrollment":276,"conditions":599,"interventions":600},[88],[278],[60,75],{"trials":602,"activeCount":99},[],{"trials":604,"activeCount":99},[],{"trials":606,"activeCount":99},[],{"intervention":50,"totalTrials":138,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":622,"PHASE4":624,"NA":626},{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":99},[],{"trials":614,"activeCount":138,"soonestReadout":49},[615],{"nctId":47,"briefTitle":48,"status":130,"phases":616,"primaryCompletion":49,"completion":617,"start":618,"enrollment":244,"conditions":619,"interventions":621},[88],"2026-05","2024-04-15",[620],"Extensive-stage Small-cell Lung Cancer",[50],{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":99},[],{"trials":627,"activeCount":99},[],{"intervention":629,"totalTrials":138,"cells":630},"Trans-Resveratrol",{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":632,"activeCount":99},[],{"trials":634,"activeCount":99},[],{"trials":636,"activeCount":138,"soonestReadout":642},[637],{"nctId":638,"briefTitle":639,"status":640,"phases":641,"primaryCompletion":642,"completion":643,"start":644,"enrollment":354,"conditions":645,"interventions":647},"NCT07592767","RESvEraTrol in Parkinson's Disease (RESET)","NOT_YET_RECRUITING",[88],"2028-06-01","2029-06-01","2026-06-01",[646],"Parkinson's Disease",[629],{"trials":649,"activeCount":99},[],{"trials":651,"activeCount":99},[],{"trials":653,"activeCount":99},[],{"intervention":223,"totalTrials":138,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":666,"PHASE4":668,"NA":670},{"trials":657,"activeCount":99},[],{"trials":659,"activeCount":99},[],{"trials":661,"activeCount":138,"soonestReadout":44},[662],{"nctId":42,"briefTitle":43,"status":130,"phases":663,"primaryCompletion":44,"completion":83,"start":219,"enrollment":199,"conditions":664,"interventions":665},[88],[221],[45,204,223],{"trials":667,"activeCount":99},[],{"trials":669,"activeCount":99},[],{"trials":671,"activeCount":99},[],{"intervention":40,"totalTrials":138,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":687,"PHASE4":689,"NA":691},{"trials":675,"activeCount":99},[],{"trials":677,"activeCount":99},[],{"trials":679,"activeCount":138,"soonestReadout":39},[680],{"nctId":37,"briefTitle":38,"status":144,"phases":681,"primaryCompletion":39,"completion":417,"start":682,"enrollment":213,"conditions":683,"interventions":685},[88],"2019-09-05",[684],"Dementia With Lewy Bodies",[40,686],"384 mg powder of K0706",{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":99},[],{"trials":692,"activeCount":99},[],{"intervention":686,"totalTrials":138,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":705,"PHASE4":707,"NA":709},{"trials":696,"activeCount":99},[],{"trials":698,"activeCount":99},[],{"trials":700,"activeCount":138,"soonestReadout":39},[701],{"nctId":37,"briefTitle":38,"status":144,"phases":702,"primaryCompletion":39,"completion":417,"start":682,"enrollment":213,"conditions":703,"interventions":704},[88],[684],[40,686],{"trials":706,"activeCount":99},[],{"trials":708,"activeCount":99},[],{"trials":710,"activeCount":99},[],{"intervention":84,"totalTrials":138,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":714,"activeCount":99},[],{"trials":716,"activeCount":99},[],{"trials":718,"activeCount":138,"soonestReadout":83},[719],{"nctId":81,"briefTitle":82,"status":144,"phases":720,"primaryCompletion":83,"completion":83,"start":721,"enrollment":555,"conditions":722,"interventions":724},[87,88],"2023-05-22",[723],"Acute Myeloid Leukemia (AML) in Remission",[84],{"trials":726,"activeCount":99},[],{"trials":728,"activeCount":99},[],{"trials":730,"activeCount":99},[],{"intervention":235,"totalTrials":138,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":138,"soonestReadout":228},[739],{"nctId":225,"briefTitle":226,"status":144,"phases":740,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":741,"interventions":742},[88],[232,233],[235,236,45],{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":99},[],{"trials":748,"activeCount":99},[],{"intervention":236,"totalTrials":138,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":752,"activeCount":99},[],{"trials":754,"activeCount":99},[],{"trials":756,"activeCount":138,"soonestReadout":228},[757],{"nctId":225,"briefTitle":226,"status":144,"phases":758,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":759,"interventions":760},[88],[232,233],[235,236,45],{"trials":762,"activeCount":99},[],{"trials":764,"activeCount":99},[],{"trials":766,"activeCount":99},[],{"intervention":65,"totalTrials":138,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":781,"PHASE4":783,"NA":785},{"trials":770,"activeCount":99},[],{"trials":772,"activeCount":99},[],{"trials":774,"activeCount":138,"soonestReadout":64},[775],{"nctId":62,"briefTitle":63,"status":144,"phases":776,"primaryCompletion":64,"completion":83,"start":777,"enrollment":9,"conditions":778,"interventions":780},[88],"2024-04-25",[779,289],"Thymoma",[65],{"trials":782,"activeCount":99},[],{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":99},[],{"intervention":788,"totalTrials":138,"cells":789},"Talazoparib",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":805,"PHASE4":807,"NA":809},{"trials":791,"activeCount":99},[],{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":138,"soonestReadout":800},[796],{"nctId":797,"briefTitle":798,"status":130,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":555,"conditions":802,"interventions":803},"NCT03964532","TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer",[87,88],"2027-04","2019-04-17",[15],[788,804],"Avelumab",{"trials":806,"activeCount":99},[],{"trials":808,"activeCount":99},[],{"trials":810,"activeCount":99},[],{"intervention":804,"totalTrials":138,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":814,"activeCount":99},[],{"trials":816,"activeCount":99},[],{"trials":818,"activeCount":138,"soonestReadout":800},[819],{"nctId":797,"briefTitle":798,"status":130,"phases":820,"primaryCompletion":800,"completion":800,"start":801,"enrollment":555,"conditions":821,"interventions":822},[87,88],[15],[788,804],{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":99},[],{"trials":828,"activeCount":99},[],{"intervention":79,"totalTrials":138,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":138,"soonestReadout":74},[837],{"nctId":77,"briefTitle":78,"status":130,"phases":838,"primaryCompletion":74,"completion":83,"start":132,"enrollment":133,"conditions":839,"interventions":840},[88],[135],[79,137,94],{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"intervention":848,"totalTrials":138,"cells":849},"NY-ESO-1 Peptide vaccine",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":851,"activeCount":99},[],{"trials":853,"activeCount":99},[],{"trials":855,"activeCount":138,"soonestReadout":274},[856],{"nctId":857,"briefTitle":858,"status":640,"phases":859,"primaryCompletion":274,"completion":860,"start":861,"enrollment":555,"conditions":862,"interventions":866},"NCT05479045","A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients",[88],"2028-11","2026-09",[863,864,865],"Ovarian Cancer Stage IV","Ovarian Cancer Stage III","Ovarian Cancer Stage 3",[848,867],"Toripalimab-tpzi",{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":99},[],{"trials":873,"activeCount":99},[],{"intervention":867,"totalTrials":138,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":877,"activeCount":99},[],{"trials":879,"activeCount":99},[],{"trials":881,"activeCount":138,"soonestReadout":274},[882],{"nctId":857,"briefTitle":858,"status":640,"phases":883,"primaryCompletion":274,"completion":860,"start":861,"enrollment":555,"conditions":884,"interventions":885},[88],[863,864,865],[848,867],{"trials":887,"activeCount":99},[],{"trials":889,"activeCount":99},[],{"trials":891,"activeCount":99},[],{"intervention":55,"totalTrials":138,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":99},[],{"trials":899,"activeCount":138,"soonestReadout":54},[900],{"nctId":52,"briefTitle":53,"status":130,"phases":901,"primaryCompletion":54,"completion":341,"start":902,"enrollment":903,"conditions":904,"interventions":906},[88],"2019-07-29",48,[905],"Advanced Biliary Tract Cancer",[55,907,908],"Leucovorin","Fluorouracil",{"trials":910,"activeCount":99},[],{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[],{"intervention":907,"totalTrials":138,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":918,"activeCount":99},[],{"trials":920,"activeCount":99},[],{"trials":922,"activeCount":138,"soonestReadout":54},[923],{"nctId":52,"briefTitle":53,"status":130,"phases":924,"primaryCompletion":54,"completion":341,"start":902,"enrollment":903,"conditions":925,"interventions":926},[88],[905],[55,907,908],{"trials":928,"activeCount":99},[],{"trials":930,"activeCount":99},[],{"trials":932,"activeCount":99},[],{"intervention":908,"totalTrials":138,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":138,"soonestReadout":54},[941],{"nctId":52,"briefTitle":53,"status":130,"phases":942,"primaryCompletion":54,"completion":341,"start":902,"enrollment":903,"conditions":943,"interventions":944},[88],[905],[55,907,908],{"trials":946,"activeCount":99},[],{"trials":948,"activeCount":99},[],{"trials":950,"activeCount":99},[],{"intervention":952,"totalTrials":138,"cells":953},"Cemiplimab-Rwlc",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":969,"PHASE4":971,"NA":973},{"trials":955,"activeCount":99},[],{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":138,"soonestReadout":379},[960],{"nctId":961,"briefTitle":962,"status":144,"phases":963,"primaryCompletion":379,"completion":964,"start":64,"enrollment":965,"conditions":966,"interventions":968},"NCT06449313","Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement",[88],"2032-09",21,[967],"Non-small Cell Lung Cancer Stage III",[952],{"trials":970,"activeCount":99},[],{"trials":972,"activeCount":99},[],{"trials":974,"activeCount":99},[],{"intervention":511,"totalTrials":138,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":987,"PHASE4":989,"NA":991},{"trials":978,"activeCount":99},[],{"trials":980,"activeCount":99},[],{"trials":982,"activeCount":138,"soonestReadout":83},[983],{"nctId":503,"briefTitle":504,"status":130,"phases":984,"primaryCompletion":83,"completion":83,"start":506,"enrollment":507,"conditions":985,"interventions":986},[88],[32],[510,483,511],{"trials":988,"activeCount":99},[],{"trials":990,"activeCount":99},[],{"trials":992,"activeCount":99},[],{"intervention":994,"totalTrials":138,"cells":995},"TTP488",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":997,"activeCount":99},[],{"trials":999,"activeCount":99},[],{"trials":1001,"activeCount":138,"soonestReadout":83},[1002],{"nctId":1003,"briefTitle":1004,"status":144,"phases":1005,"primaryCompletion":83,"completion":83,"start":1006,"enrollment":903,"conditions":1007,"interventions":1010},"NCT05256745","RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer",[87,88],"2023-06-06",[1008,1009],"Cancer Related Cognitive Decline","Non-metastatic Breast Cancer",[994,1011,1012,1013,1014],"ddAC\u002FddT","TC","TCHP","Chemotherapy regimen that includes ddAC",{"trials":1016,"activeCount":99},[],{"trials":1018,"activeCount":99},[],{"trials":1020,"activeCount":99},[],{"intervention":1011,"totalTrials":138,"cells":1022},{"EARLY_PHASE1":1023,"PHASE1":1025,"PHASE2":1027,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1024,"activeCount":99},[],{"trials":1026,"activeCount":99},[],{"trials":1028,"activeCount":138,"soonestReadout":83},[1029],{"nctId":1003,"briefTitle":1004,"status":144,"phases":1030,"primaryCompletion":83,"completion":83,"start":1006,"enrollment":903,"conditions":1031,"interventions":1032},[87,88],[1008,1009],[994,1011,1012,1013,1014],{"trials":1034,"activeCount":99},[],{"trials":1036,"activeCount":99},[],{"trials":1038,"activeCount":99},[],{"intervention":1012,"totalTrials":138,"cells":1040},{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1042,"activeCount":99},[],{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":138,"soonestReadout":83},[1047],{"nctId":1003,"briefTitle":1004,"status":144,"phases":1048,"primaryCompletion":83,"completion":83,"start":1006,"enrollment":903,"conditions":1049,"interventions":1050},[87,88],[1008,1009],[994,1011,1012,1013,1014],{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"intervention":1013,"totalTrials":138,"cells":1058},{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1069,"PHASE4":1071,"NA":1073},{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":138,"soonestReadout":83},[1065],{"nctId":1003,"briefTitle":1004,"status":144,"phases":1066,"primaryCompletion":83,"completion":83,"start":1006,"enrollment":903,"conditions":1067,"interventions":1068},[87,88],[1008,1009],[994,1011,1012,1013,1014],{"trials":1070,"activeCount":99},[],{"trials":1072,"activeCount":99},[],{"trials":1074,"activeCount":99},[],{"intervention":1014,"totalTrials":138,"cells":1076},{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1087,"PHASE4":1089,"NA":1091},{"trials":1078,"activeCount":99},[],{"trials":1080,"activeCount":99},[],{"trials":1082,"activeCount":138,"soonestReadout":83},[1083],{"nctId":1003,"briefTitle":1004,"status":144,"phases":1084,"primaryCompletion":83,"completion":83,"start":1006,"enrollment":903,"conditions":1085,"interventions":1086},[87,88],[1008,1009],[994,1011,1012,1013,1014],{"trials":1088,"activeCount":99},[],{"trials":1090,"activeCount":99},[],{"trials":1092,"activeCount":99},[],{"intervention":1094,"totalTrials":162,"cells":1095},"Doxorubicin",{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1110,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1097,"activeCount":99},[],{"trials":1099,"activeCount":138,"soonestReadout":353},[1100],{"nctId":1101,"briefTitle":1102,"status":144,"phases":1103,"primaryCompletion":353,"completion":353,"start":1104,"enrollment":555,"conditions":1105,"interventions":1108},"NCT05661201","NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors",[87],"2023-04-12",[1106,1107],"Solid Tumor","KRAS Mutation-Related Tumors",[1109,1094],"NEROFE",{"trials":1111,"activeCount":99},[1112],{"nctId":1113,"briefTitle":1114,"status":107,"phases":1115,"primaryCompletion":1116,"completion":1116,"start":1117,"enrollment":321,"conditions":1118,"interventions":1120},"NCT02261805","A Phase I\u002FII Study of Ganetespib in Combination With Doxorubicin",[87,88],"2016-10","2014-10",[1119,246],"Cancer",[1121,1094],"Ganetespib",{"trials":1123,"activeCount":99},[],{"trials":1125,"activeCount":99},[],{"trials":1127,"activeCount":99},[],{"intervention":1109,"totalTrials":138,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1131,"activeCount":99},[],{"trials":1133,"activeCount":138,"soonestReadout":353},[1134],{"nctId":1101,"briefTitle":1102,"status":144,"phases":1135,"primaryCompletion":353,"completion":353,"start":1104,"enrollment":555,"conditions":1136,"interventions":1137},[87],[1106,1107],[1109,1094],{"trials":1139,"activeCount":99},[],{"trials":1141,"activeCount":99},[],{"trials":1143,"activeCount":99},[],{"trials":1145,"activeCount":99},[],{"intervention":1147,"totalTrials":162,"cells":1148},"Etanercept",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1181},{"trials":1150,"activeCount":99},[],{"trials":1152,"activeCount":99},[1153],{"nctId":1154,"briefTitle":1155,"status":208,"phases":1156,"completion":1157,"enrollment":1158,"conditions":1159,"interventions":1161},"NCT00091741","Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects",[87],"2004-10",10,[1160],"HIV Infection",[1147],{"trials":1163,"activeCount":99},[],{"trials":1165,"activeCount":99},[],{"trials":1167,"activeCount":99},[1168],{"nctId":1169,"briefTitle":1170,"status":283,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1178},"NCT01793519","Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis",[90],"2024-06-30","2024-08-30","2013-01",290,[1177],"Rheumatoid Arthritis",[1147,1179,1180],"Infliximab","Adalimumab",{"trials":1182,"activeCount":99},[],{"intervention":1184,"totalTrials":138,"cells":1185},"Dornase alfa",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1206},{"trials":1187,"activeCount":99},[],{"trials":1189,"activeCount":99},[],{"trials":1191,"activeCount":99},[],{"trials":1193,"activeCount":99},[],{"trials":1195,"activeCount":99},[1196],{"nctId":1197,"briefTitle":1198,"status":208,"phases":1199,"primaryCompletion":1200,"completion":1201,"start":1202,"enrollment":321,"conditions":1203,"interventions":1205},"NCT01356147","Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)",[90],"2015-01","2017-04-30","2011-05",[1204],"Pulmonary Infections",[1184],{"trials":1207,"activeCount":99},[],{"intervention":1209,"totalTrials":138,"cells":1210},"Escitalopram",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1236},{"trials":1212,"activeCount":99},[],{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"trials":1218,"activeCount":99},[],{"trials":1220,"activeCount":99},[1221],{"nctId":1222,"briefTitle":1223,"status":208,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1235},"NCT03522844","Treatments for Anxiety: Meditation and Escitalopram",[90],"2021-10-31","2022-01-05","2018-06-18",276,[1230,1231,1232,1233,1234],"Anxiety Disorders","Generalized Anxiety Disorder","Panic Disorder","Social Anxiety Disorder","Agoraphobia",[1209],{"trials":1237,"activeCount":99},[],{"intervention":1239,"totalTrials":138,"cells":1240},"Myfortic",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1263},{"trials":1242,"activeCount":99},[],{"trials":1244,"activeCount":99},[],{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":99},[1251],{"nctId":1252,"briefTitle":1253,"status":388,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":99,"conditions":1257,"interventions":1261},"NCT01149993","Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation",[90],"2012-06","2010-06",[1258,1259,1260],"Kidney Transplantation","Renal Transplantation","Reperfusion Injury",[1239,1239,1262,1262],"Thymoglobulin",{"trials":1264,"activeCount":99},[],{"intervention":1262,"totalTrials":138,"cells":1266},{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1275,"NA":1281},{"trials":1268,"activeCount":99},[],{"trials":1270,"activeCount":99},[],{"trials":1272,"activeCount":99},[],{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[1277],{"nctId":1252,"briefTitle":1253,"status":388,"phases":1278,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":99,"conditions":1279,"interventions":1280},[90],[1258,1259,1260],[1239,1239,1262,1262],{"trials":1282,"activeCount":99},[],{"intervention":1179,"totalTrials":138,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1291,"PHASE4":1293,"NA":1299},{"trials":1286,"activeCount":99},[],{"trials":1288,"activeCount":99},[],{"trials":1290,"activeCount":99},[],{"trials":1292,"activeCount":99},[],{"trials":1294,"activeCount":99},[1295],{"nctId":1169,"briefTitle":1170,"status":283,"phases":1296,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":1297,"interventions":1298},[90],[1177],[1147,1179,1180],{"trials":1300,"activeCount":99},[],{"intervention":1180,"totalTrials":138,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1309,"PHASE4":1311,"NA":1317},{"trials":1304,"activeCount":99},[],{"trials":1306,"activeCount":99},[],{"trials":1308,"activeCount":99},[],{"trials":1310,"activeCount":99},[],{"trials":1312,"activeCount":99},[1313],{"nctId":1169,"briefTitle":1170,"status":283,"phases":1314,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":1315,"interventions":1316},[90],[1177],[1147,1179,1180],{"trials":1318,"activeCount":99},[],{"intervention":1320,"totalTrials":138,"cells":1321},"HepaGam B",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1342},{"trials":1323,"activeCount":99},[],{"trials":1325,"activeCount":99},[],{"trials":1327,"activeCount":99},[],{"trials":1329,"activeCount":99},[],{"trials":1331,"activeCount":99},[1332],{"nctId":1333,"briefTitle":1334,"status":208,"phases":1335,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":30,"conditions":1339,"interventions":1341},"NCT00998426","Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients",[90],"2011-09","2011-12","2009-10",[1340],"Hepatitis B",[1320],{"trials":1343,"activeCount":99},[],{"intervention":1345,"totalTrials":138,"cells":1346},"Amiloride",{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1355,"NA":1367},{"trials":1348,"activeCount":99},[],{"trials":1350,"activeCount":99},[],{"trials":1352,"activeCount":99},[],{"trials":1354,"activeCount":99},[],{"trials":1356,"activeCount":99},[1357],{"nctId":1358,"briefTitle":1359,"status":283,"phases":1360,"primaryCompletion":1361,"completion":1361,"start":1362,"enrollment":354,"conditions":1363,"interventions":1365},"NCT02522650","A Crossover Pilot Study of the Effect of Amiloride on Proteinuria",[90],"2021-10","2013-07",[1364],"Proteinuria",[1345,1366],"Triamterene",{"trials":1368,"activeCount":99},[],{"intervention":1366,"totalTrials":138,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1385},{"trials":1372,"activeCount":99},[],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"trials":1380,"activeCount":99},[1381],{"nctId":1358,"briefTitle":1359,"status":283,"phases":1382,"primaryCompletion":1361,"completion":1361,"start":1362,"enrollment":354,"conditions":1383,"interventions":1384},[90],[1364],[1345,1366],{"trials":1386,"activeCount":99},[],{"intervention":1388,"totalTrials":138,"cells":1389},"Istradefylline Pill",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1398,"NA":1412},{"trials":1391,"activeCount":99},[],{"trials":1393,"activeCount":99},[],{"trials":1395,"activeCount":99},[],{"trials":1397,"activeCount":99},[],{"trials":1399,"activeCount":99},[1400],{"nctId":1401,"briefTitle":1402,"status":208,"phases":1403,"primaryCompletion":1404,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1411},"NCT05885360","Istradefylline Effect Protocol on Parkinson's Disease Tremor",[90],"2024-02-23","2025-02-21","2023-01-20",27,[1409,1410],"Parkinson Disease","Tremor",[1388],{"trials":1413,"activeCount":99},[],{"intervention":1415,"totalTrials":138,"cells":1416},"Botox",{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1425,"NA":1440},{"trials":1418,"activeCount":99},[],{"trials":1420,"activeCount":99},[],{"trials":1422,"activeCount":99},[],{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[1427],{"nctId":1428,"briefTitle":1429,"status":208,"phases":1430,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":1158,"conditions":1433,"interventions":1438},"NCT02052024","Myobloc Atrophy Study",[90],"2015-08","2014-05",[1434,1435,1436,1437,21],"Spasticity Secondary to Either a Disorder or Trauma","Spinal Cord Injury (SCI)","Brain Injury","Tumor",[1415,1439],"MYOBLOC",{"trials":1441,"activeCount":99},[],{"intervention":1439,"totalTrials":138,"cells":1443},{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1458},{"trials":1445,"activeCount":99},[],{"trials":1447,"activeCount":99},[],{"trials":1449,"activeCount":99},[],{"trials":1451,"activeCount":99},[],{"trials":1453,"activeCount":99},[1454],{"nctId":1428,"briefTitle":1429,"status":208,"phases":1455,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":1158,"conditions":1456,"interventions":1457},[90],[1434,1435,1436,1437,21],[1415,1439],{"trials":1459,"activeCount":99},[],{"intervention":1461,"totalTrials":138,"cells":1462},"Exenatide",{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1471,"NA":1482},{"trials":1464,"activeCount":99},[],{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"trials":1472,"activeCount":99},[1473],{"nctId":1474,"briefTitle":1475,"status":388,"phases":1476,"primaryCompletion":1431,"completion":1431,"start":1477,"enrollment":99,"conditions":1478,"interventions":1480},"NCT00572689","Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes",[90],"2013-08",[1479],"Gestational Diabetes",[1461,1481],"Buccal\u002Fblood Sample Collection",{"trials":1483,"activeCount":99},[],{"intervention":1481,"totalTrials":138,"cells":1485},{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1494,"NA":1500},{"trials":1487,"activeCount":99},[],{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[],{"trials":1495,"activeCount":99},[1496],{"nctId":1474,"briefTitle":1475,"status":388,"phases":1497,"primaryCompletion":1431,"completion":1431,"start":1477,"enrollment":99,"conditions":1498,"interventions":1499},[90],[1479],[1461,1481],{"trials":1501,"activeCount":99},[],{"intervention":1503,"totalTrials":138,"cells":1504},"Benzalkonium Gel",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1513,"NA":1525},{"trials":1506,"activeCount":99},[],{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[1515],{"nctId":1516,"briefTitle":1517,"status":208,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":321,"conditions":1521,"interventions":1523},"NCT03686904","Investigation of a Novel Wound Gel to Improve Wound Healing in Chronic Wounds",[90],"2020-02-14","2018-11-19",[1522],"Wound Infection",[1503,1524],"benzalkonium irrigation",{"trials":1526,"activeCount":99},[],{"intervention":1524,"totalTrials":138,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1543},{"trials":1530,"activeCount":99},[],{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[1539],{"nctId":1516,"briefTitle":1517,"status":208,"phases":1540,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":321,"conditions":1541,"interventions":1542},[90],[1522],[1503,1524],{"trials":1544,"activeCount":99},[],{"intervention":1546,"totalTrials":138,"cells":1547},"Rasagiline\u002FPlacebo",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1567},{"trials":1549,"activeCount":99},[],{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[],{"trials":1557,"activeCount":99},[1558],{"nctId":1559,"briefTitle":1560,"status":208,"phases":1561,"primaryCompletion":287,"completion":287,"start":1562,"enrollment":1563,"conditions":1564,"interventions":1565},"NCT01497652","A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy",[90],"2012-01",34,[646],[1546,1566],"Rasagiline",{"trials":1568,"activeCount":99},[],{"intervention":1566,"totalTrials":138,"cells":1570},{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1585},{"trials":1572,"activeCount":99},[],{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":99},[],{"trials":1580,"activeCount":99},[1581],{"nctId":1559,"briefTitle":1560,"status":208,"phases":1582,"primaryCompletion":287,"completion":287,"start":1562,"enrollment":1563,"conditions":1583,"interventions":1584},[90],[646],[1546,1566],{"trials":1586,"activeCount":99},[],{"intervention":1588,"totalTrials":138,"cells":1589},"Normal saline",{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1598,"NA":1610},{"trials":1591,"activeCount":99},[],{"trials":1593,"activeCount":99},[],{"trials":1595,"activeCount":99},[],{"trials":1597,"activeCount":99},[],{"trials":1599,"activeCount":99},[1600],{"nctId":1601,"briefTitle":1602,"status":208,"phases":1603,"primaryCompletion":1604,"completion":1605,"start":1606,"enrollment":1607,"conditions":1608,"interventions":1609},"NCT01939145","Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation",[90],"2014-07","2016-07","2013-09",100,[1522],[1588],{"trials":1611,"activeCount":99},[],{"intervention":1613,"totalTrials":138,"cells":1614},"INTEGRA™ Flowable Matrix",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1634},{"trials":1616,"activeCount":99},[],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[1625],{"nctId":1626,"briefTitle":1627,"status":107,"phases":1628,"primaryCompletion":1629,"completion":1629,"start":1256,"enrollment":30,"conditions":1630,"interventions":1633},"NCT01108263","Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers",[90],"2011-08",[1631,1632],"Diabetes","Foot Ulcer",[1613],{"trials":1635,"activeCount":99},[],{"intervention":1637,"totalTrials":138,"cells":1638},"Ropivacaine",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1659},{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":99},[],{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":99},[],{"trials":1648,"activeCount":99},[1649],{"nctId":1650,"briefTitle":1651,"status":283,"phases":1652,"primaryCompletion":1653,"completion":1654,"start":1605,"enrollment":1655,"conditions":1656,"interventions":1658},"NCT02851888","Use of Regional Anesthesia in Hip Arthroscopy",[90],"2018-04","2018-08",70,[1657],"Hip Injuries",[1637],{"trials":1660,"activeCount":99},[],{"intervention":1662,"totalTrials":138,"cells":1663},"Sitagliptin",{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1670,"PHASE4":1672,"NA":1682},{"trials":1665,"activeCount":99},[],{"trials":1667,"activeCount":99},[],{"trials":1669,"activeCount":99},[],{"trials":1671,"activeCount":99},[],{"trials":1673,"activeCount":99},[1674],{"nctId":1675,"briefTitle":1676,"status":107,"phases":1677,"primaryCompletion":1200,"completion":1200,"start":1678,"enrollment":138,"conditions":1679,"interventions":1681},"NCT02015910","Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers",[90],"2014-01",[1680],"Type II Diabetes",[1662],{"trials":1683,"activeCount":99},[],{"intervention":1685,"totalTrials":138,"cells":1686},"Ribociclib",{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1693,"PHASE4":1695,"NA":1705},{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[],{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":99},[],{"trials":1696,"activeCount":99},[1697],{"nctId":1698,"briefTitle":1699,"status":107,"phases":1700,"primaryCompletion":1701,"completion":1701,"start":1702,"enrollment":965,"conditions":1703,"interventions":1704},"NCT04657679","Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts",[90],"2023-10-30","2021-05-20",[15],[1685],{"trials":1706,"activeCount":99},[],{"intervention":1708,"totalTrials":138,"cells":1709},"Efavirenz 600mg",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1730,"NA":1732},{"trials":1711,"activeCount":99},[],{"trials":1713,"activeCount":99},[],{"trials":1715,"activeCount":99},[],{"trials":1717,"activeCount":99},[1718],{"nctId":1719,"briefTitle":1720,"status":208,"phases":1721,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":1726,"interventions":1728},"NCT00727597","A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT",[89],"2010-08","2011-07","2008-07",101,[1727],"Human Immunodeficiency Virus Infections",[1708,1729],"Boosted Lexiva",{"trials":1731,"activeCount":99},[],{"trials":1733,"activeCount":99},[],{"intervention":1729,"totalTrials":138,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1748,"NA":1750},{"trials":1737,"activeCount":99},[],{"trials":1739,"activeCount":99},[],{"trials":1741,"activeCount":99},[],{"trials":1743,"activeCount":99},[1744],{"nctId":1719,"briefTitle":1720,"status":208,"phases":1745,"primaryCompletion":1722,"completion":1723,"start":1724,"enrollment":1725,"conditions":1746,"interventions":1747},[89],[1727],[1708,1729],{"trials":1749,"activeCount":99},[],{"trials":1751,"activeCount":99},[],{"intervention":1753,"totalTrials":138,"cells":1754},"Rituxan",{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1761,"PHASE4":1773,"NA":1775},{"trials":1756,"activeCount":99},[],{"trials":1758,"activeCount":99},[],{"trials":1760,"activeCount":99},[],{"trials":1762,"activeCount":99},[1763],{"nctId":1764,"briefTitle":1765,"status":107,"phases":1766,"primaryCompletion":1767,"completion":1629,"start":1768,"enrollment":162,"conditions":1769,"interventions":1771},"NCT00306670","Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A",[88,89],"2011-01","2006-04",[1770],"Hemophilia A",[1753,1772],"prednisone",{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"intervention":1772,"totalTrials":138,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1791,"NA":1793},{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[],{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[1787],{"nctId":1764,"briefTitle":1765,"status":107,"phases":1788,"primaryCompletion":1767,"completion":1629,"start":1768,"enrollment":162,"conditions":1789,"interventions":1790},[88,89],[1770],[1753,1772],{"trials":1792,"activeCount":99},[],{"trials":1794,"activeCount":99},[],{"intervention":1796,"totalTrials":138,"cells":1797},"Bifidobacterium lactis",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1816,"NA":1818},{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[],{"trials":1805,"activeCount":99},[1806],{"nctId":1807,"briefTitle":1808,"status":208,"phases":1809,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":1812,"conditions":1813,"interventions":1815},"NCT00492583","Study to Investigate the Potential of Probiotics in Yogurt",[89],"2008-08","2007-07",182,[1814],"Healthy",[1796],{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[],{"intervention":1821,"totalTrials":138,"cells":1822},"Palbociclib + Letrozole or Fulvestrant",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1841,"NA":1843},{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[],{"trials":1828,"activeCount":99},[],{"trials":1830,"activeCount":99},[1831],{"nctId":1832,"briefTitle":1833,"status":208,"phases":1834,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":266,"conditions":1838,"interventions":1840},"NCT02692755","Palbociclib \u002F Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer",[88,89],"2019-12-16","2021-03-23","2016-09",[1839],"Hormone Receptor Positive HER-2 Negative Breast Cancer",[1821],{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[],{"intervention":1846,"totalTrials":138,"cells":1847},"Lactobacillus (L.) casei",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1854,"PHASE4":1865,"NA":1867},{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[1856],{"nctId":1857,"briefTitle":1858,"status":208,"phases":1859,"primaryCompletion":1860,"completion":1860,"start":1861,"enrollment":1862,"conditions":1863,"interventions":1864},"NCT00356382","Decreasing Rates of Illness in Kids (DRINK)",[89],"2007-06","2006-09",638,[1814],[1846],{"trials":1866,"activeCount":99},[],{"trials":1868,"activeCount":99},[],{"intervention":1870,"totalTrials":366,"cells":1871},"ABT-888",{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1873,"activeCount":99},[],{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":99},[1878,1886,1897],{"nctId":1879,"briefTitle":1880,"status":107,"phases":1881,"primaryCompletion":1117,"completion":1117,"start":1722,"enrollment":1882,"conditions":1883,"interventions":1884},"NCT01205828","ABT-888 and Temozolomide for Liver Cancer",[88],16,[153],[1885,1870],"Temozolomide",{"nctId":1887,"briefTitle":1888,"status":208,"phases":1889,"primaryCompletion":1890,"completion":1891,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1895},"NCT01489865","ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer",[87,88],"2018-12-26","2023-12-07","2011-01-03",64,[34],[1870,1896],"mFOLFOX-6",{"nctId":1898,"briefTitle":1899,"status":208,"phases":1900,"primaryCompletion":1901,"completion":1902,"start":1903,"enrollment":1904,"conditions":1905,"interventions":1906},"NCT01051596","A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer",[88],"2013-06","2013-12","2009-09",75,[24],[1885,1870],{"trials":1908,"activeCount":99},[],{"trials":1910,"activeCount":99},[],{"trials":1912,"activeCount":99},[],{"intervention":1914,"totalTrials":162,"cells":1915},"paclitaxel",{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1917,"activeCount":99},[],{"trials":1919,"activeCount":99},[],{"trials":1921,"activeCount":99},[1922,1933],{"nctId":1923,"briefTitle":1924,"status":208,"phases":1925,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":11,"conditions":1928,"interventions":1929},"NCT00003035","Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer",[88],"2001-06","1997-03",[15],[1930,1931,1914,1932],"filgrastim","doxorubicin hydrochloride","tamoxifen citrate",{"nctId":1934,"briefTitle":1935,"status":107,"phases":1936,"primaryCompletion":1937,"completion":1937,"start":1938,"enrollment":276,"conditions":1939,"interventions":1940},"NCT00088829","Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer",[88],"2012-12","2001-04",[15],[1914,1941,1942],"microarray analysis","Paclitaxel",{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[],{"trials":1948,"activeCount":99},[],{"intervention":1885,"totalTrials":162,"cells":1950},{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[],{"trials":1956,"activeCount":99},[1957,1961],{"nctId":1879,"briefTitle":1880,"status":107,"phases":1958,"primaryCompletion":1117,"completion":1117,"start":1722,"enrollment":1882,"conditions":1959,"interventions":1960},[88],[153],[1885,1870],{"nctId":1898,"briefTitle":1899,"status":208,"phases":1962,"primaryCompletion":1901,"completion":1902,"start":1903,"enrollment":1904,"conditions":1963,"interventions":1964},[88],[24],[1885,1870],{"trials":1966,"activeCount":99},[],{"trials":1968,"activeCount":99},[],{"trials":1970,"activeCount":99},[],{"intervention":1972,"totalTrials":162,"cells":1973},"Nilotinib",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1989,"PHASE3":2001,"PHASE4":2003,"NA":2005},{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[1978],{"nctId":1979,"briefTitle":1980,"status":208,"phases":1981,"primaryCompletion":1982,"start":1983,"enrollment":1984,"conditions":1985,"interventions":1988},"NCT02281474","Nilotinib in Cognitively Impaired Parkinson Disease Patients 001",[87],"2015-05","2014-11",12,[646,1986,1987],"Parkinson's Disease Dementia","Diffuse Lewy Body Disease",[1972],{"trials":1990,"activeCount":99},[1991],{"nctId":1992,"briefTitle":1993,"status":208,"phases":1994,"primaryCompletion":1995,"completion":1995,"start":1996,"enrollment":1997,"conditions":1998,"interventions":1999},"NCT04002674","Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies",[88],"2025-04-30","2019-07-01",43,[684],[2000],"Nilotinib Oral",{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[],{"intervention":128,"totalTrials":162,"cells":2008},{"EARLY_PHASE1":2009,"PHASE1":2011,"PHASE2":2013,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2010,"activeCount":99},[],{"trials":2012,"activeCount":99},[],{"trials":2014,"activeCount":99},[2015,2019],{"nctId":206,"briefTitle":207,"status":208,"phases":2016,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":2017,"interventions":2018},[88],[215],[45,128],{"nctId":116,"briefTitle":117,"status":107,"phases":2020,"primaryCompletion":119,"completion":120,"start":121,"enrollment":19,"conditions":2021,"interventions":2022},[87,88],[112,123,124,34],[126,127,128,94],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"intervention":2030,"totalTrials":162,"cells":2031},"Palbociclib",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2051,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2033,"activeCount":99},[],{"trials":2035,"activeCount":99},[2036],{"nctId":2037,"briefTitle":2038,"status":208,"phases":2039,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":2044,"interventions":2048},"NCT03854903","WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4\u002F6 Inhibitor",[87],"2023-11-01","2025-01-09","2019-04-01",19,[2045,2046,2047],"Metastatic Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Hormone Receptor Positive Breast Cancer",[2030,2049,2050],"Bosutinib","Fulvestrant",{"trials":2052,"activeCount":99},[2053],{"nctId":2054,"briefTitle":2055,"status":107,"phases":2056,"primaryCompletion":2057,"completion":2057,"start":2058,"enrollment":2059,"conditions":2060,"interventions":2062},"NCT03535506","Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery",[88],"2023-12-06","2018-10-08",17,[2061],"DCIS",[2030],{"trials":2064,"activeCount":99},[],{"trials":2066,"activeCount":99},[],{"trials":2068,"activeCount":99},[],{"intervention":2070,"totalTrials":162,"cells":2071},"Dovitinib",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[2078,2088],{"nctId":2079,"briefTitle":2080,"status":107,"phases":2081,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":1984,"conditions":2085,"interventions":2086},"NCT01484041","Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer",[87,88],"2015-12","2017-12","2012-04",[15],[2070,2087],"Aromatase Inhibitors",{"nctId":2089,"briefTitle":2090,"status":107,"phases":2091,"primaryCompletion":2092,"completion":1117,"start":2093,"enrollment":244,"conditions":2094,"interventions":2096},"NCT01888965","Maintenance Dovitinib for Colorectal and Pancreas Cancer",[88],"2014-08","2013-10",[24,2095],"Pancreas Cancer",[2070],{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[],{"trials":2102,"activeCount":99},[],{"intervention":2049,"totalTrials":162,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2113,"PHASE3":2125,"PHASE4":2127,"NA":2129},{"trials":2106,"activeCount":99},[],{"trials":2108,"activeCount":99},[2109],{"nctId":2037,"briefTitle":2038,"status":208,"phases":2110,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":2111,"interventions":2112},[87],[2045,2046,2047],[2030,2049,2050],{"trials":2114,"activeCount":99},[2115],{"nctId":2116,"briefTitle":2117,"status":208,"phases":2118,"primaryCompletion":2119,"completion":2119,"start":2120,"enrollment":2121,"conditions":2122,"interventions":2123},"NCT03888222","Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies",[88],"2021-08-27","2019-04-23",26,[684],[2124],"Bosutinib Oral",{"trials":2126,"activeCount":99},[],{"trials":2128,"activeCount":99},[],{"trials":2130,"activeCount":99},[],{"intervention":1930,"totalTrials":138,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2143,"PHASE4":2145,"NA":2147},{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[],{"trials":2138,"activeCount":99},[2139],{"nctId":1923,"briefTitle":1924,"status":208,"phases":2140,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":11,"conditions":2141,"interventions":2142},[88],[15],[1930,1931,1914,1932],{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[],{"trials":2148,"activeCount":99},[],{"intervention":1931,"totalTrials":138,"cells":2150},{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2161,"PHASE4":2163,"NA":2165},{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[],{"trials":2156,"activeCount":99},[2157],{"nctId":1923,"briefTitle":1924,"status":208,"phases":2158,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":11,"conditions":2159,"interventions":2160},[88],[15],[1930,1931,1914,1932],{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":99},[],{"trials":2166,"activeCount":99},[],{"intervention":1932,"totalTrials":138,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2179,"PHASE4":2181,"NA":2183},{"trials":2170,"activeCount":99},[],{"trials":2172,"activeCount":99},[],{"trials":2174,"activeCount":99},[2175],{"nctId":1923,"briefTitle":1924,"status":208,"phases":2176,"primaryCompletion":1926,"completion":1926,"start":1927,"enrollment":11,"conditions":2177,"interventions":2178},[88],[15],[1930,1931,1914,1932],{"trials":2180,"activeCount":99},[],{"trials":2182,"activeCount":99},[],{"trials":2184,"activeCount":99},[],{"intervention":2186,"totalTrials":138,"cells":2187},"Gem-OX",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2189,"activeCount":99},[],{"trials":2191,"activeCount":99},[],{"trials":2193,"activeCount":99},[2194],{"nctId":2195,"briefTitle":2196,"status":208,"phases":2197,"primaryCompletion":2198,"completion":2199,"start":1937,"enrollment":2043,"conditions":2200,"interventions":2201},"NCT01888978","Molecularly Tailored Therapy for Pancreas Cancer",[88],"2016-06","2018-01-24",[29],[2186,2202,2203,2204,2205,2206,2207],"Gem-5FU","Gem-Tax","Modified FOLFOX-6","Ox-Tax","FOLFIRI","Tax-Iri",{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[],{"trials":2213,"activeCount":99},[],{"intervention":2202,"totalTrials":138,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2226,"PHASE4":2228,"NA":2230},{"trials":2217,"activeCount":99},[],{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[2222],{"nctId":2195,"briefTitle":2196,"status":208,"phases":2223,"primaryCompletion":2198,"completion":2199,"start":1937,"enrollment":2043,"conditions":2224,"interventions":2225},[88],[29],[2186,2202,2203,2204,2205,2206,2207],{"trials":2227,"activeCount":99},[],{"trials":2229,"activeCount":99},[],{"trials":2231,"activeCount":99},[],{"intervention":2203,"totalTrials":138,"cells":2233},{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2244,"PHASE4":2246,"NA":2248},{"trials":2235,"activeCount":99},[],{"trials":2237,"activeCount":99},[],{"trials":2239,"activeCount":99},[2240],{"nctId":2195,"briefTitle":2196,"status":208,"phases":2241,"primaryCompletion":2198,"completion":2199,"start":1937,"enrollment":2043,"conditions":2242,"interventions":2243},[88],[29],[2186,2202,2203,2204,2205,2206,2207],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[],{"intervention":2204,"totalTrials":138,"cells":2251},{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2253,"activeCount":99},[],{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[2258],{"nctId":2195,"briefTitle":2196,"status":208,"phases":2259,"primaryCompletion":2198,"completion":2199,"start":1937,"enrollment":2043,"conditions":2260,"interventions":2261},[88],[29],[2186,2202,2203,2204,2205,2206,2207],{"trials":2263,"activeCount":99},[],{"trials":2265,"activeCount":99},[],{"trials":2267,"activeCount":99},[],{"intervention":2205,"totalTrials":138,"cells":2269},{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":99},[],{"trials":2275,"activeCount":99},[2276],{"nctId":2195,"briefTitle":2196,"status":208,"phases":2277,"primaryCompletion":2198,"completion":2199,"start":1937,"enrollment":2043,"conditions":2278,"interventions":2279},[88],[29],[2186,2202,2203,2204,2205,2206,2207],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"intervention":2206,"totalTrials":138,"cells":2287},{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2298,"PHASE4":2300,"NA":2302},{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[],{"trials":2293,"activeCount":99},[2294],{"nctId":2195,"briefTitle":2196,"status":208,"phases":2295,"primaryCompletion":2198,"completion":2199,"start":1937,"enrollment":2043,"conditions":2296,"interventions":2297},[88],[29],[2186,2202,2203,2204,2205,2206,2207],{"trials":2299,"activeCount":99},[],{"trials":2301,"activeCount":99},[],{"trials":2303,"activeCount":99},[],{"intervention":2207,"totalTrials":138,"cells":2305},{"EARLY_PHASE1":2306,"PHASE1":2308,"PHASE2":2310,"PHASE3":2316,"PHASE4":2318,"NA":2320},{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"trials":2311,"activeCount":99},[2312],{"nctId":2195,"briefTitle":2196,"status":208,"phases":2313,"primaryCompletion":2198,"completion":2199,"start":1937,"enrollment":2043,"conditions":2314,"interventions":2315},[88],[29],[2186,2202,2203,2204,2205,2206,2207],{"trials":2317,"activeCount":99},[],{"trials":2319,"activeCount":99},[],{"trials":2321,"activeCount":99},[],{"intervention":2323,"totalTrials":138,"cells":2324},"LEE011",{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2326,"activeCount":99},[],{"trials":2328,"activeCount":99},[],{"trials":2330,"activeCount":99},[2331],{"nctId":2332,"briefTitle":2333,"status":208,"phases":2334,"primaryCompletion":2335,"completion":2336,"start":2337,"enrollment":1984,"conditions":2338,"interventions":2340},"NCT02985125","LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy",[87,88],"2019-07-24","2020-09-28","2017-05-04",[2339],"Metastatic Pancreatic Adenocarcinoma",[2323,2341],"Everolimus",{"trials":2343,"activeCount":99},[],{"trials":2345,"activeCount":99},[],{"trials":2347,"activeCount":99},[],{"intervention":2341,"totalTrials":138,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2360,"PHASE4":2362,"NA":2364},{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":99},[],{"trials":2355,"activeCount":99},[2356],{"nctId":2332,"briefTitle":2333,"status":208,"phases":2357,"primaryCompletion":2335,"completion":2336,"start":2337,"enrollment":1984,"conditions":2358,"interventions":2359},[87,88],[2339],[2323,2341],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[],{"trials":2365,"activeCount":99},[],{"intervention":2367,"totalTrials":138,"cells":2368},"Nilotinib Capsule(s) Once a Day by Mouth",{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2386,"PHASE4":2388,"NA":2390},{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[2375],{"nctId":2376,"briefTitle":2377,"status":208,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":2382,"conditions":2383,"interventions":2385},"NCT02947893","Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease",[88],"2020-12","2021-03","2017-01",37,[2384],"Alzheimer's Disease",[2367],{"trials":2387,"activeCount":99},[],{"trials":2389,"activeCount":99},[],{"trials":2391,"activeCount":99},[],{"intervention":2393,"totalTrials":138,"cells":2394},"Bosentan",{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2396,"activeCount":99},[],{"trials":2398,"activeCount":99},[],{"trials":2400,"activeCount":99},[2401],{"nctId":2402,"briefTitle":2403,"status":107,"phases":2404,"primaryCompletion":1903,"completion":2405,"start":1861,"enrollment":30,"conditions":2406,"interventions":2409},"NCT00377455","Placebo Controlled Trial of Bosentan in Scleroderma Patients",[88],"2010-03",[2407,2408],"Systemic Scleroderma","Pulmonary Hypertension",[2393],{"trials":2411,"activeCount":99},[],{"trials":2413,"activeCount":99},[],{"trials":2415,"activeCount":99},[],{"intervention":2417,"totalTrials":138,"cells":2418},"Panitumumab and bortezomib",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2432,"PHASE4":2434,"NA":2436},{"trials":2420,"activeCount":99},[],{"trials":2422,"activeCount":99},[],{"trials":2424,"activeCount":99},[2425],{"nctId":2426,"briefTitle":2427,"status":107,"phases":2428,"primaryCompletion":2429,"completion":2429,"start":1337,"enrollment":27,"conditions":2430,"interventions":2431},"NCT01504477","Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer",[87,88],"2014-02",[24],[2417],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[],{"intervention":2439,"totalTrials":138,"cells":2440},"Exemestane",{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2456,"PHASE4":2458,"NA":2460},{"trials":2442,"activeCount":99},[],{"trials":2444,"activeCount":99},[],{"trials":2446,"activeCount":99},[2447],{"nctId":2448,"briefTitle":2449,"status":208,"phases":2450,"primaryCompletion":1337,"completion":1337,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2455},"NCT00073073","Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer",[88],"2003-11",46,[2454],"Breast Neoplasms",[2439],{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"intervention":2463,"totalTrials":138,"cells":2464},"Albumin",{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2478,"PHASE4":2480,"NA":2482},{"trials":2466,"activeCount":99},[],{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[2471],{"nctId":2472,"briefTitle":2473,"status":107,"phases":2474,"primaryCompletion":1901,"completion":1901,"start":1903,"enrollment":199,"conditions":2475,"interventions":2477},"NCT00990509","Albumin for Intracerebral Hemorrhage Intervention",[88],[2476],"Intracerebral Hemorrhage",[2463],{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"trials":2483,"activeCount":99},[],{"intervention":2485,"totalTrials":138,"cells":2486},"Liposomal bupivacaine",{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2501,"PHASE4":2503,"NA":2505},{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[],{"trials":2492,"activeCount":99},[2493],{"nctId":2494,"briefTitle":2495,"status":283,"phases":2496,"primaryCompletion":2379,"completion":286,"start":1996,"enrollment":1607,"conditions":2497,"interventions":2499},"NCT03504865","Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo",[88],[2498,15],"Mastectomy",[2485,2500],"Standard bupivacaine",{"trials":2502,"activeCount":99},[],{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"intervention":2500,"totalTrials":138,"cells":2508},{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2510,"activeCount":99},[],{"trials":2512,"activeCount":99},[],{"trials":2514,"activeCount":99},[2515],{"nctId":2494,"briefTitle":2495,"status":283,"phases":2516,"primaryCompletion":2379,"completion":286,"start":1996,"enrollment":1607,"conditions":2517,"interventions":2518},[88],[2498,15],[2485,2500],{"trials":2520,"activeCount":99},[],{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":99},[],{"intervention":114,"totalTrials":138,"cells":2526},{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[],{"trials":2532,"activeCount":99},[2533],{"nctId":105,"briefTitle":106,"status":107,"phases":2534,"primaryCompletion":109,"completion":109,"start":110,"enrollment":95,"conditions":2535,"interventions":2536},[88],[112],[114,94],{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"intervention":500,"totalTrials":138,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"trials":2550,"activeCount":99},[2551],{"nctId":492,"briefTitle":493,"status":208,"phases":2552,"primaryCompletion":495,"completion":496,"start":497,"enrollment":276,"conditions":2553,"interventions":2554},[88],[32],[483,500,501],{"trials":2556,"activeCount":99},[],{"trials":2558,"activeCount":99},[],{"trials":2560,"activeCount":99},[],{"intervention":501,"totalTrials":138,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[2569],{"nctId":492,"briefTitle":493,"status":208,"phases":2570,"primaryCompletion":495,"completion":496,"start":497,"enrollment":276,"conditions":2571,"interventions":2572},[88],[32],[483,500,501],{"trials":2574,"activeCount":99},[],{"trials":2576,"activeCount":99},[],{"trials":2578,"activeCount":99},[],{"intervention":2580,"totalTrials":138,"cells":2581},"Galantamine",{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2598,"PHASE4":2600,"NA":2602},{"trials":2583,"activeCount":99},[],{"trials":2585,"activeCount":99},[],{"trials":2587,"activeCount":99},[2588],{"nctId":2589,"briefTitle":2590,"status":208,"phases":2591,"primaryCompletion":495,"completion":495,"start":2592,"enrollment":1997,"conditions":2593,"interventions":2595},"NCT00509067","Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia",[88],"2007-11",[2594],"Schizophrenia",[2580,2596,2597],"CDP-choline","risperidone, olanzapine, quetiapine, ziprasidone, and\u002For aripiprazole",{"trials":2599,"activeCount":99},[],{"trials":2601,"activeCount":99},[],{"trials":2603,"activeCount":99},[],{"intervention":2596,"totalTrials":138,"cells":2605},{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[],{"trials":2611,"activeCount":99},[2612],{"nctId":2589,"briefTitle":2590,"status":208,"phases":2613,"primaryCompletion":495,"completion":495,"start":2592,"enrollment":1997,"conditions":2614,"interventions":2615},[88],[2594],[2580,2596,2597],{"trials":2617,"activeCount":99},[],{"trials":2619,"activeCount":99},[],{"trials":2621,"activeCount":99},[],{"intervention":2597,"totalTrials":138,"cells":2623},{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2634,"PHASE4":2636,"NA":2638},{"trials":2625,"activeCount":99},[],{"trials":2627,"activeCount":99},[],{"trials":2629,"activeCount":99},[2630],{"nctId":2589,"briefTitle":2590,"status":208,"phases":2631,"primaryCompletion":495,"completion":495,"start":2592,"enrollment":1997,"conditions":2632,"interventions":2633},[88],[2594],[2580,2596,2597],{"trials":2635,"activeCount":99},[],{"trials":2637,"activeCount":99},[],{"trials":2639,"activeCount":99},[],{"intervention":2641,"totalTrials":138,"cells":2642},"Vemurafenib",{"EARLY_PHASE1":2643,"PHASE1":2645,"PHASE2":2647,"PHASE3":2659,"PHASE4":2661,"NA":2663},{"trials":2644,"activeCount":99},[],{"trials":2646,"activeCount":99},[],{"trials":2648,"activeCount":99},[2649],{"nctId":2650,"briefTitle":2651,"status":107,"phases":2652,"primaryCompletion":2653,"completion":2654,"start":2655,"enrollment":30,"conditions":2656,"interventions":2657},"NCT01813214","The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma",[88],"2016-08","2016-12","2013-03",[221],[2641,2658],"Cobimetinib",{"trials":2660,"activeCount":99},[],{"trials":2662,"activeCount":99},[],{"trials":2664,"activeCount":99},[],{"intervention":2658,"totalTrials":138,"cells":2666},{"EARLY_PHASE1":2667,"PHASE1":2669,"PHASE2":2671,"PHASE3":2677,"PHASE4":2679,"NA":2681},{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[2673],{"nctId":2650,"briefTitle":2651,"status":107,"phases":2674,"primaryCompletion":2653,"completion":2654,"start":2655,"enrollment":30,"conditions":2675,"interventions":2676},[88],[221],[2641,2658],{"trials":2678,"activeCount":99},[],{"trials":2680,"activeCount":99},[],{"trials":2682,"activeCount":99},[],{"intervention":2684,"totalTrials":138,"cells":2685},"mitoxantrone hydrochloride",{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2690,"PHASE3":2704,"PHASE4":2706,"NA":2708},{"trials":2687,"activeCount":99},[],{"trials":2689,"activeCount":99},[],{"trials":2691,"activeCount":99},[2692],{"nctId":2693,"briefTitle":2694,"status":208,"phases":2695,"primaryCompletion":2696,"completion":2696,"start":2697,"enrollment":2698,"conditions":2699,"interventions":2701},"NCT00003297","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer",[87,88],"2001-01","1997-12",50,[2700],"Ovarian Cancer",[2684,2702,2703],"thiotepa","topotecan hydrochloride",{"trials":2705,"activeCount":99},[],{"trials":2707,"activeCount":99},[],{"trials":2709,"activeCount":99},[],{"intervention":2702,"totalTrials":138,"cells":2711},{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2722,"PHASE4":2724,"NA":2726},{"trials":2713,"activeCount":99},[],{"trials":2715,"activeCount":99},[],{"trials":2717,"activeCount":99},[2718],{"nctId":2693,"briefTitle":2694,"status":208,"phases":2719,"primaryCompletion":2696,"completion":2696,"start":2697,"enrollment":2698,"conditions":2720,"interventions":2721},[87,88],[2700],[2684,2702,2703],{"trials":2723,"activeCount":99},[],{"trials":2725,"activeCount":99},[],{"trials":2727,"activeCount":99},[],{"intervention":2703,"totalTrials":138,"cells":2729},{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[2736],{"nctId":2693,"briefTitle":2694,"status":208,"phases":2737,"primaryCompletion":2696,"completion":2696,"start":2697,"enrollment":2698,"conditions":2738,"interventions":2739},[87,88],[2700],[2684,2702,2703],{"trials":2741,"activeCount":99},[],{"trials":2743,"activeCount":99},[],{"trials":2745,"activeCount":99},[],{"intervention":2747,"totalTrials":138,"cells":2748},"Daratumumab and hyaluronidase-fihj",{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2753,"PHASE3":2764,"PHASE4":2766,"NA":2768},{"trials":2750,"activeCount":99},[],{"trials":2752,"activeCount":99},[],{"trials":2754,"activeCount":99},[2755],{"nctId":2756,"briefTitle":2757,"status":388,"phases":2758,"primaryCompletion":2759,"completion":2759,"start":2759,"enrollment":99,"conditions":2760,"interventions":2763},"NCT06046287","Daratumumab for Polyneuropathy Associated With MGUS",[88],"2025-09-26",[2761,2762],"Peripheral Neuropathy","Monoclonal Gammopathy of Undetermined Significance",[2747],{"trials":2765,"activeCount":99},[],{"trials":2767,"activeCount":99},[],{"trials":2769,"activeCount":99},[],{"intervention":293,"totalTrials":138,"cells":2771},{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2773,"activeCount":99},[],{"trials":2775,"activeCount":99},[],{"trials":2777,"activeCount":99},[2778],{"nctId":281,"briefTitle":282,"status":283,"phases":2779,"primaryCompletion":285,"completion":286,"start":287,"enrollment":213,"conditions":2780,"interventions":2781},[88],[289,290,291],[75,293],{"trials":2783,"activeCount":99},[],{"trials":2785,"activeCount":99},[],{"trials":2787,"activeCount":99},[],{"intervention":2789,"totalTrials":138,"cells":2790},"Carnosine",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2795,"PHASE3":2806,"PHASE4":2808,"NA":2810},{"trials":2792,"activeCount":99},[],{"trials":2794,"activeCount":99},[],{"trials":2796,"activeCount":99},[2797],{"nctId":2798,"briefTitle":2799,"status":208,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":1810,"enrollment":2802,"conditions":2803,"interventions":2805},"NCT00810368","Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)",[88],"2012-07",33,[2804],"Persian Gulf Syndrome",[2789],{"trials":2807,"activeCount":99},[],{"trials":2809,"activeCount":99},[],{"trials":2811,"activeCount":99},[],{"intervention":2813,"totalTrials":138,"cells":2814},"pemetrexed",{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2829,"PHASE4":2831,"NA":2833},{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":99},[],{"trials":2820,"activeCount":99},[2821],{"nctId":2822,"briefTitle":2823,"status":107,"phases":2824,"primaryCompletion":2825,"completion":2825,"start":2826,"enrollment":2059,"conditions":2827,"interventions":2828},"NCT00864513","Study of Pemetrexed for Second-Line Pancreas Cancer",[88],"2009-07","2007-10",[2095],[2813],{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[],{"intervention":127,"totalTrials":138,"cells":2836},{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2847,"PHASE4":2849,"NA":2851},{"trials":2838,"activeCount":99},[],{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[2843],{"nctId":116,"briefTitle":117,"status":107,"phases":2844,"primaryCompletion":119,"completion":120,"start":121,"enrollment":19,"conditions":2845,"interventions":2846},[87,88],[112,123,124,34],[126,127,128,94],{"trials":2848,"activeCount":99},[],{"trials":2850,"activeCount":99},[],{"trials":2852,"activeCount":99},[],{"intervention":1121,"totalTrials":138,"cells":2854},{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2859,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2856,"activeCount":99},[],{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[2861],{"nctId":1113,"briefTitle":1114,"status":107,"phases":2862,"primaryCompletion":1116,"completion":1116,"start":1117,"enrollment":321,"conditions":2863,"interventions":2864},[87,88],[1119,246],[1121,1094],{"trials":2866,"activeCount":99},[],{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[],{"intervention":2872,"totalTrials":138,"cells":2873},"Standard of Care Second Line Therapy",{"EARLY_PHASE1":2874,"PHASE1":2876,"PHASE2":2878,"PHASE3":2888,"PHASE4":2890,"NA":2892},{"trials":2875,"activeCount":99},[],{"trials":2877,"activeCount":99},[],{"trials":2879,"activeCount":99},[2880],{"nctId":2881,"briefTitle":2882,"status":388,"phases":2883,"primaryCompletion":2884,"completion":2884,"start":2885,"enrollment":99,"conditions":2886,"interventions":2887},"NCT02967770","Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer",[88],"2018-08-30","2016-11",[34],[2872],{"trials":2889,"activeCount":99},[],{"trials":2891,"activeCount":99},[],{"trials":2893,"activeCount":99},[],{"intervention":2895,"totalTrials":138,"cells":2896},"Gemcitabine and Abraxane",{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2901,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2898,"activeCount":99},[],{"trials":2900,"activeCount":99},[],{"trials":2902,"activeCount":99},[2903],{"nctId":2904,"briefTitle":2905,"status":107,"phases":2906,"primaryCompletion":2654,"completion":2654,"start":2907,"enrollment":95,"conditions":2908,"interventions":2909},"NCT02242409","Study of Gemcitabine and Abraxane for Pancreas Cancer",[88],"2014-09",[29],[2895],{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":99},[],{"intervention":2917,"totalTrials":138,"cells":2918},"acetazolamide",{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2923,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2920,"activeCount":99},[],{"trials":2922,"activeCount":99},[],{"trials":2924,"activeCount":99},[2925],{"nctId":2926,"briefTitle":2927,"status":388,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":99,"conditions":2931,"interventions":2934},"NCT02276989","Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain",[88],"2016-01","2014-12",[2932,2933],"Compliance","Chronic Pain",[2917,2935,2936],"Quinine","Riboflavin",{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[],{"trials":2942,"activeCount":99},[],{"intervention":2935,"totalTrials":138,"cells":2944},{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2955,"PHASE4":2957,"NA":2959},{"trials":2946,"activeCount":99},[],{"trials":2948,"activeCount":99},[],{"trials":2950,"activeCount":99},[2951],{"nctId":2926,"briefTitle":2927,"status":388,"phases":2952,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":99,"conditions":2953,"interventions":2954},[88],[2932,2933],[2917,2935,2936],{"trials":2956,"activeCount":99},[],{"trials":2958,"activeCount":99},[],{"trials":2960,"activeCount":99},[],{"intervention":2936,"totalTrials":138,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2964,"activeCount":99},[],{"trials":2966,"activeCount":99},[],{"trials":2968,"activeCount":99},[2969],{"nctId":2926,"briefTitle":2927,"status":388,"phases":2970,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":99,"conditions":2971,"interventions":2972},[88],[2932,2933],[2917,2935,2936],{"trials":2974,"activeCount":99},[],{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[],{"intervention":560,"totalTrials":138,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2982,"activeCount":99},[],{"trials":2984,"activeCount":99},[],{"trials":2986,"activeCount":99},[2987],{"nctId":549,"briefTitle":550,"status":208,"phases":2988,"primaryCompletion":552,"completion":553,"start":554,"enrollment":555,"conditions":2989,"interventions":2990},[87,88],[557,558],[560,510],{"trials":2992,"activeCount":99},[],{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"intervention":2998,"totalTrials":138,"cells":2999},"chemotherapy and GI-4000",{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3015,"PHASE4":3017,"NA":3019},{"trials":3001,"activeCount":99},[],{"trials":3003,"activeCount":99},[],{"trials":3005,"activeCount":99},[3006],{"nctId":3007,"briefTitle":3008,"status":107,"phases":3009,"primaryCompletion":2907,"completion":2082,"start":3010,"enrollment":321,"conditions":3011,"interventions":3013},"NCT01322815","A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI",[88],"2010-10",[3012],"Colon Cancer",[2998,3014],"GI-4000",{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[],{"intervention":3014,"totalTrials":138,"cells":3022},{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3033,"PHASE4":3035,"NA":3037},{"trials":3024,"activeCount":99},[],{"trials":3026,"activeCount":99},[],{"trials":3028,"activeCount":99},[3029],{"nctId":3007,"briefTitle":3008,"status":107,"phases":3030,"primaryCompletion":2907,"completion":2082,"start":3010,"enrollment":321,"conditions":3031,"interventions":3032},[88],[3012],[2998,3014],{"trials":3034,"activeCount":99},[],{"trials":3036,"activeCount":99},[],{"trials":3038,"activeCount":99},[],{"intervention":3040,"totalTrials":138,"cells":3041},"\"Bevacizumab\" in combination with \"modified FOLFOX6\".",{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3046,"PHASE3":3056,"PHASE4":3058,"NA":3060},{"trials":3043,"activeCount":99},[],{"trials":3045,"activeCount":99},[],{"trials":3047,"activeCount":99},[3048],{"nctId":3049,"briefTitle":3050,"status":107,"phases":3051,"primaryCompletion":3052,"completion":1337,"start":3053,"enrollment":244,"conditions":3054,"interventions":3055},"NCT00881504","A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma",[88],"2011-02","2009-06",[394],[3040],{"trials":3057,"activeCount":99},[],{"trials":3059,"activeCount":99},[],{"trials":3061,"activeCount":99},[],{"intervention":2087,"totalTrials":138,"cells":3063},{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3074,"PHASE4":3076,"NA":3078},{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[],{"trials":3069,"activeCount":99},[3070],{"nctId":2079,"briefTitle":2080,"status":107,"phases":3071,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":1984,"conditions":3072,"interventions":3073},[87,88],[15],[2070,2087],{"trials":3075,"activeCount":99},[],{"trials":3077,"activeCount":99},[],{"trials":3079,"activeCount":99},[],{"intervention":304,"totalTrials":138,"cells":3081},{"EARLY_PHASE1":3082,"PHASE1":3084,"PHASE2":3086,"PHASE3":3092,"PHASE4":3094,"NA":3096},{"trials":3083,"activeCount":99},[],{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[3088],{"nctId":295,"briefTitle":296,"status":208,"phases":3089,"primaryCompletion":298,"completion":299,"start":300,"enrollment":199,"conditions":3090,"interventions":3091},[88],[302],[75,304],{"trials":3093,"activeCount":99},[],{"trials":3095,"activeCount":99},[],{"trials":3097,"activeCount":99},[],{"intervention":3099,"totalTrials":138,"cells":3100},"Lapatinib and Capecitabine",{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3102,"activeCount":99},[],{"trials":3104,"activeCount":99},[],{"trials":3106,"activeCount":99},[3107],{"nctId":3108,"briefTitle":3109,"status":107,"phases":3110,"primaryCompletion":1937,"completion":1901,"start":3111,"enrollment":2059,"conditions":3112,"interventions":3113},"NCT00881621","Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer",[88],"2009-08",[2095],[3099],{"trials":3115,"activeCount":99},[],{"trials":3117,"activeCount":99},[],{"trials":3119,"activeCount":99},[],{"intervention":3121,"totalTrials":138,"cells":3122},"Estrace",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3140,"PHASE4":3142,"NA":3144},{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[],{"trials":3128,"activeCount":99},[3129],{"nctId":3130,"briefTitle":3131,"status":107,"phases":3132,"primaryCompletion":3133,"completion":3133,"start":3134,"enrollment":321,"conditions":3135,"interventions":3138},"NCT00661531","Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy",[88],"2015-06","2008-04",[15,3136,3137],"Cancer of the Breast","Neoplasms, Breast",[3121,3139],"Anastrozole",{"trials":3141,"activeCount":99},[],{"trials":3143,"activeCount":99},[],{"trials":3145,"activeCount":99},[],{"intervention":3139,"totalTrials":138,"cells":3147},{"EARLY_PHASE1":3148,"PHASE1":3150,"PHASE2":3152,"PHASE3":3158,"PHASE4":3160,"NA":3162},{"trials":3149,"activeCount":99},[],{"trials":3151,"activeCount":99},[],{"trials":3153,"activeCount":99},[3154],{"nctId":3130,"briefTitle":3131,"status":107,"phases":3155,"primaryCompletion":3133,"completion":3133,"start":3134,"enrollment":321,"conditions":3156,"interventions":3157},[88],[15,3136,3137],[3121,3139],{"trials":3159,"activeCount":99},[],{"trials":3161,"activeCount":99},[],{"trials":3163,"activeCount":99},[],{"intervention":1896,"totalTrials":138,"cells":3165},{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3170,"PHASE3":3176,"PHASE4":3178,"NA":3180},{"trials":3167,"activeCount":99},[],{"trials":3169,"activeCount":99},[],{"trials":3171,"activeCount":99},[3172],{"nctId":1887,"briefTitle":1888,"status":208,"phases":3173,"primaryCompletion":1890,"completion":1891,"start":1892,"enrollment":1893,"conditions":3174,"interventions":3175},[87,88],[34],[1870,1896],{"trials":3177,"activeCount":99},[],{"trials":3179,"activeCount":99},[],{"trials":3181,"activeCount":99},[],{"intervention":3183,"totalTrials":138,"cells":3184},"Ofatumumab and Bendamustine",{"EARLY_PHASE1":3185,"PHASE1":3187,"PHASE2":3189,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3186,"activeCount":99},[],{"trials":3188,"activeCount":99},[],{"trials":3190,"activeCount":99},[3191],{"nctId":3192,"briefTitle":3193,"status":107,"phases":3194,"primaryCompletion":1432,"completion":2092,"start":3195,"enrollment":1158,"conditions":3196,"interventions":3198},"NCT01010568","Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)",[88],"2010-04",[32,3197],"Small Lymphocytic Lymphoma",[3183],{"trials":3200,"activeCount":99},[],{"trials":3202,"activeCount":99},[],{"trials":3204,"activeCount":99},[],{"intervention":3206,"totalTrials":138,"cells":3207},"VX-853",{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3223,"PHASE4":3225,"NA":3227},{"trials":3209,"activeCount":99},[],{"trials":3211,"activeCount":99},[],{"trials":3213,"activeCount":99},[3214],{"nctId":3215,"briefTitle":3216,"status":208,"phases":3217,"primaryCompletion":2696,"completion":2696,"start":3218,"enrollment":213,"conditions":3219,"interventions":3221},"NCT00004030","VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin",[87,88],"1996-03",[3220],"Unspecified Adult Solid Tumor, Protocol Specific",[3206,3222],"pegylated liposomal doxorubicin hydrochloride",{"trials":3224,"activeCount":99},[],{"trials":3226,"activeCount":99},[],{"trials":3228,"activeCount":99},[],{"intervention":3222,"totalTrials":138,"cells":3230},{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3241,"PHASE4":3243,"NA":3245},{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":99},[],{"trials":3236,"activeCount":99},[3237],{"nctId":3215,"briefTitle":3216,"status":208,"phases":3238,"primaryCompletion":2696,"completion":2696,"start":3218,"enrollment":213,"conditions":3239,"interventions":3240},[87,88],[3220],[3206,3222],{"trials":3242,"activeCount":99},[],{"trials":3244,"activeCount":99},[],{"trials":3246,"activeCount":99},[],{"intervention":3248,"totalTrials":138,"cells":3249},"Regorafenib",{"EARLY_PHASE1":3250,"PHASE1":3252,"PHASE2":3254,"PHASE3":3263,"PHASE4":3265,"NA":3267},{"trials":3251,"activeCount":99},[],{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":99},[3256],{"nctId":3257,"briefTitle":3258,"status":107,"phases":3259,"primaryCompletion":109,"completion":109,"start":3260,"enrollment":1158,"conditions":3261,"interventions":3262},"NCT02402036","A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer",[88],"2015-02",[3012],[3248],{"trials":3264,"activeCount":99},[],{"trials":3266,"activeCount":99},[],{"trials":3268,"activeCount":99},[],{"intervention":3270,"totalTrials":138,"cells":3271},"SM-88",{"EARLY_PHASE1":3272,"PHASE1":3274,"PHASE2":3276,"PHASE3":3287,"PHASE4":3289,"NA":3291},{"trials":3273,"activeCount":99},[],{"trials":3275,"activeCount":99},[],{"trials":3277,"activeCount":99},[3278],{"nctId":3279,"briefTitle":3280,"status":107,"phases":3281,"primaryCompletion":3282,"completion":3282,"start":3283,"enrollment":321,"conditions":3284,"interventions":3286},"NCT04720664","Oral SM-88 in Patients With Metastatic HR+\u002FHER2- Breast Cancer",[88],"2023-02-10","2021-09-22",[15,2045,3285],"Hormone Receptor Positive Breast Carcinoma",[3270],{"trials":3288,"activeCount":99},[],{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[],{"intervention":3294,"totalTrials":138,"cells":3295},"ALVAC-CEA vaccine",{"EARLY_PHASE1":3296,"PHASE1":3298,"PHASE2":3300,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3297,"activeCount":99},[],{"trials":3299,"activeCount":99},[],{"trials":3301,"activeCount":99},[3302],{"nctId":3303,"briefTitle":3304,"status":208,"phases":3305,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":555,"conditions":3308,"interventions":3311},"NCT00003125","Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors",[88],"2004-11","1998-01",[15,3309,3310,26,29,3220],"Esophageal Cancer","Gastric Cancer",[3294,3312,3313,3314],"aldesleukin","sargramostim","vaccinia-CEA vaccine",{"trials":3316,"activeCount":99},[],{"trials":3318,"activeCount":99},[],{"trials":3320,"activeCount":99},[],{"intervention":3312,"totalTrials":138,"cells":3322},{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3333,"PHASE4":3335,"NA":3337},{"trials":3324,"activeCount":99},[],{"trials":3326,"activeCount":99},[],{"trials":3328,"activeCount":99},[3329],{"nctId":3303,"briefTitle":3304,"status":208,"phases":3330,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":555,"conditions":3331,"interventions":3332},[88],[15,3309,3310,26,29,3220],[3294,3312,3313,3314],{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[],{"trials":3338,"activeCount":99},[],{"intervention":3313,"totalTrials":138,"cells":3340},{"EARLY_PHASE1":3341,"PHASE1":3343,"PHASE2":3345,"PHASE3":3351,"PHASE4":3353,"NA":3355},{"trials":3342,"activeCount":99},[],{"trials":3344,"activeCount":99},[],{"trials":3346,"activeCount":99},[3347],{"nctId":3303,"briefTitle":3304,"status":208,"phases":3348,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":555,"conditions":3349,"interventions":3350},[88],[15,3309,3310,26,29,3220],[3294,3312,3313,3314],{"trials":3352,"activeCount":99},[],{"trials":3354,"activeCount":99},[],{"trials":3356,"activeCount":99},[],{"intervention":3314,"totalTrials":138,"cells":3358},{"EARLY_PHASE1":3359,"PHASE1":3361,"PHASE2":3363,"PHASE3":3369,"PHASE4":3371,"NA":3373},{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[],{"trials":3364,"activeCount":99},[3365],{"nctId":3303,"briefTitle":3304,"status":208,"phases":3366,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":555,"conditions":3367,"interventions":3368},[88],[15,3309,3310,26,29,3220],[3294,3312,3313,3314],{"trials":3370,"activeCount":99},[],{"trials":3372,"activeCount":99},[],{"trials":3374,"activeCount":99},[],{"intervention":3376,"totalTrials":138,"cells":3377},"Nilotinib 150mg oral capsule [Tasigna]",{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3394,"PHASE4":3396,"NA":3398},{"trials":3379,"activeCount":99},[],{"trials":3381,"activeCount":99},[],{"trials":3383,"activeCount":99},[3384],{"nctId":3385,"briefTitle":3386,"status":283,"phases":3387,"primaryCompletion":3388,"completion":3389,"start":2381,"enrollment":1904,"conditions":3390,"interventions":3392},"NCT02954978","Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease",[88],"2020-05","2020-07",[1409,3391],"Parkinsons Disease With Dementia",[3376,3393],"Nilotinib 300mg oral capsule [Tasigna]",{"trials":3395,"activeCount":99},[],{"trials":3397,"activeCount":99},[],{"trials":3399,"activeCount":99},[],{"intervention":3393,"totalTrials":138,"cells":3401},{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3406,"PHASE3":3412,"PHASE4":3414,"NA":3416},{"trials":3403,"activeCount":99},[],{"trials":3405,"activeCount":99},[],{"trials":3407,"activeCount":99},[3408],{"nctId":3385,"briefTitle":3386,"status":283,"phases":3409,"primaryCompletion":3388,"completion":3389,"start":2381,"enrollment":1904,"conditions":3410,"interventions":3411},[88],[1409,3391],[3376,3393],{"trials":3413,"activeCount":99},[],{"trials":3415,"activeCount":99},[],{"trials":3417,"activeCount":99},[],{"intervention":3419,"totalTrials":138,"cells":3420},"Pregabalin",{"EARLY_PHASE1":3421,"PHASE1":3423,"PHASE2":3425,"PHASE3":3433,"PHASE4":3435,"NA":3437},{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[3427],{"nctId":3428,"briefTitle":3429,"status":107,"phases":3430,"primaryCompletion":110,"completion":110,"start":2655,"enrollment":95,"conditions":3431,"interventions":3432},"NCT01821430","Increased Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids",[88],[2933],[3419],{"trials":3434,"activeCount":99},[],{"trials":3436,"activeCount":99},[],{"trials":3438,"activeCount":99},[],{"intervention":3440,"totalTrials":138,"cells":3441},"sunitinib and capecitabine",{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3446,"PHASE3":3454,"PHASE4":3456,"NA":3458},{"trials":3443,"activeCount":99},[],{"trials":3445,"activeCount":99},[],{"trials":3447,"activeCount":99},[3448],{"nctId":3449,"briefTitle":3450,"status":107,"phases":3451,"primaryCompletion":495,"completion":495,"start":3111,"enrollment":2698,"conditions":3452,"interventions":3453},"NCT00961571","Sunitinib and Capecitabine for First Line Colon Cancer",[88],[112],[3440],{"trials":3455,"activeCount":99},[],{"trials":3457,"activeCount":99},[],{"trials":3459,"activeCount":99},[],{"intervention":3461,"totalTrials":138,"cells":3462},"Bifidobacterium animalis subsp. lactis BB-12",{"EARLY_PHASE1":3463,"PHASE1":3465,"PHASE2":3467,"PHASE3":3479,"PHASE4":3481,"NA":3483},{"trials":3464,"activeCount":99},[],{"trials":3466,"activeCount":99},[],{"trials":3468,"activeCount":99},[3469],{"nctId":3470,"briefTitle":3471,"status":208,"phases":3472,"primaryCompletion":3473,"completion":3473,"start":3474,"enrollment":3475,"conditions":3476,"interventions":3478},"NCT03181516","Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics",[88],"2023-10-11","2017-09-30",255,[3477],"Antibiotic-associated Diarrhea",[3461],{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[],{"trials":3484,"activeCount":99},[],{"intervention":3486,"totalTrials":138,"cells":3487},"Open Label Selinexor",{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3504,"PHASE4":3506,"NA":3508},{"trials":3489,"activeCount":99},[],{"trials":3491,"activeCount":99},[],{"trials":3493,"activeCount":99},[3494],{"nctId":3495,"briefTitle":3496,"status":107,"phases":3497,"primaryCompletion":3498,"completion":3499,"start":3500,"enrollment":19,"conditions":3501,"interventions":3503},"NCT03193437","Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy",[88],"2020-07-27","2022-01-31","2018-04-03",[779,3502],"Advanced Thymic Epithelial Tumor",[3486],{"trials":3505,"activeCount":99},[],{"trials":3507,"activeCount":99},[],{"trials":3509,"activeCount":99},[],{"intervention":3511,"totalTrials":138,"cells":3512},"Bifidobacterium animalis subsp. lactis strain BB-12",{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3524,"PHASE3":3526,"PHASE4":3528,"NA":3530},{"trials":3514,"activeCount":99},[],{"trials":3516,"activeCount":99},[3517],{"nctId":3518,"briefTitle":3519,"status":208,"phases":3520,"primaryCompletion":1723,"completion":1723,"start":1338,"enrollment":11,"conditions":3521,"interventions":3523},"NCT00848003","Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics",[87],[3522],"Adults on Antibiotics",[3511],{"trials":3525,"activeCount":99},[],{"trials":3527,"activeCount":99},[],{"trials":3529,"activeCount":99},[],{"trials":3531,"activeCount":99},[],{"intervention":3533,"totalTrials":138,"cells":3534},"mFOLFIRINOX",{"EARLY_PHASE1":3535,"PHASE1":3537,"PHASE2":3549,"PHASE3":3551,"PHASE4":3553,"NA":3555},{"trials":3536,"activeCount":99},[],{"trials":3538,"activeCount":99},[3539],{"nctId":3540,"briefTitle":3541,"status":208,"phases":3542,"primaryCompletion":3543,"completion":3544,"start":3545,"enrollment":244,"conditions":3546,"interventions":3548},"NCT03885284","Study of Proton Therapy in Adjuvant Pancreatic Cancer",[87],"2022-05-24","2023-11-08","2019-07-15",[3547],"Resected Pancreatic Adenocarcinoma",[3533],{"trials":3550,"activeCount":99},[],{"trials":3552,"activeCount":99},[],{"trials":3554,"activeCount":99},[],{"trials":3556,"activeCount":99},[],{"intervention":3558,"totalTrials":138,"cells":3559},"Nilotinib 150 MG",{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3573,"PHASE3":3575,"PHASE4":3577,"NA":3579},{"trials":3561,"activeCount":99},[],{"trials":3563,"activeCount":99},[3564],{"nctId":3565,"briefTitle":3566,"status":283,"phases":3567,"primaryCompletion":3568,"completion":3568,"start":3569,"enrollment":1158,"conditions":3570,"interventions":3572},"NCT03764215","Nilotinib in Huntington's Disease",[87],"2020-11-30","2018-11-15",[3571],"Huntington Disease",[3558],{"trials":3574,"activeCount":99},[],{"trials":3576,"activeCount":99},[],{"trials":3578,"activeCount":99},[],{"trials":3580,"activeCount":99},[],{"intervention":3582,"totalTrials":138,"cells":3583},"Niraparib",{"EARLY_PHASE1":3584,"PHASE1":3586,"PHASE2":3600,"PHASE3":3602,"PHASE4":3604,"NA":3606},{"trials":3585,"activeCount":99},[],{"trials":3587,"activeCount":99},[3588],{"nctId":3589,"briefTitle":3590,"status":107,"phases":3591,"primaryCompletion":3592,"completion":3592,"start":3593,"enrollment":3594,"conditions":3595,"interventions":3598},"NCT03209401","Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies",[87],"2023-10-16","2017-10-13",23,[3596,3597],"Solid Tumor, Adult","Homologous Recombination Deficiency",[3582,3599],"Carboplatin",{"trials":3601,"activeCount":99},[],{"trials":3603,"activeCount":99},[],{"trials":3605,"activeCount":99},[],{"trials":3607,"activeCount":99},[],{"intervention":3599,"totalTrials":138,"cells":3609},{"EARLY_PHASE1":3610,"PHASE1":3612,"PHASE2":3618,"PHASE3":3620,"PHASE4":3622,"NA":3624},{"trials":3611,"activeCount":99},[],{"trials":3613,"activeCount":99},[3614],{"nctId":3589,"briefTitle":3590,"status":107,"phases":3615,"primaryCompletion":3592,"completion":3592,"start":3593,"enrollment":3594,"conditions":3616,"interventions":3617},[87],[3596,3597],[3582,3599],{"trials":3619,"activeCount":99},[],{"trials":3621,"activeCount":99},[],{"trials":3623,"activeCount":99},[],{"trials":3625,"activeCount":99},[],{"intervention":3627,"totalTrials":138,"cells":3628},"PD-0332991",{"EARLY_PHASE1":3629,"PHASE1":3631,"PHASE2":3642,"PHASE3":3644,"PHASE4":3646,"NA":3648},{"trials":3630,"activeCount":99},[],{"trials":3632,"activeCount":99},[3633],{"nctId":3634,"briefTitle":3635,"status":283,"phases":3636,"primaryCompletion":2379,"completion":2379,"start":1337,"enrollment":2382,"conditions":3637,"interventions":3639},"NCT01522989","PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies",[87],[3638],"Advanced Solid Tumor Malignancies",[3627,3640,3641],"5-FU","Oxaliplatin",{"trials":3643,"activeCount":99},[],{"trials":3645,"activeCount":99},[],{"trials":3647,"activeCount":99},[],{"trials":3649,"activeCount":99},[],{"intervention":3640,"totalTrials":138,"cells":3651},{"EARLY_PHASE1":3652,"PHASE1":3654,"PHASE2":3660,"PHASE3":3662,"PHASE4":3664,"NA":3666},{"trials":3653,"activeCount":99},[],{"trials":3655,"activeCount":99},[3656],{"nctId":3634,"briefTitle":3635,"status":283,"phases":3657,"primaryCompletion":2379,"completion":2379,"start":1337,"enrollment":2382,"conditions":3658,"interventions":3659},[87],[3638],[3627,3640,3641],{"trials":3661,"activeCount":99},[],{"trials":3663,"activeCount":99},[],{"trials":3665,"activeCount":99},[],{"trials":3667,"activeCount":99},[],{"intervention":3641,"totalTrials":138,"cells":3669},{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3678,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[3674],{"nctId":3634,"briefTitle":3635,"status":283,"phases":3675,"primaryCompletion":2379,"completion":2379,"start":1337,"enrollment":2382,"conditions":3676,"interventions":3677},[87],[3638],[3627,3640,3641],{"trials":3679,"activeCount":99},[],{"trials":3681,"activeCount":99},[],{"trials":3683,"activeCount":99},[],{"trials":3685,"activeCount":99},[],{"intervention":3687,"totalTrials":138,"cells":3688},"Temsirolimus and capecitabine",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3702,"PHASE3":3704,"PHASE4":3706,"NA":3708},{"trials":3690,"activeCount":99},[],{"trials":3692,"activeCount":99},[3693],{"nctId":3694,"briefTitle":3695,"status":208,"phases":3696,"primaryCompletion":2655,"completion":1901,"start":3697,"enrollment":3698,"conditions":3699,"interventions":3701},"NCT01050985","A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer",[87],"2010-07",47,[3700],"Advanced Solid Tumors",[3687],{"trials":3703,"activeCount":99},[],{"trials":3705,"activeCount":99},[],{"trials":3707,"activeCount":99},[],{"trials":3709,"activeCount":99},[],{"intervention":3711,"totalTrials":138,"cells":3712},"Eryaspase",{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3728,"PHASE3":3730,"PHASE4":3732,"NA":3734},{"trials":3714,"activeCount":99},[],{"trials":3716,"activeCount":99},[3717],{"nctId":3718,"briefTitle":3719,"status":208,"phases":3720,"primaryCompletion":3721,"completion":3722,"start":3723,"enrollment":2043,"conditions":3724,"interventions":3726},"NCT04292743","Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma",[87],"2023-01-18","2024-03-04","2020-12-02",[3725,278],"Locally Advanced Pancreatic Ductal Adenocarcinoma",[3711,3727],"FOLFIRINOX",{"trials":3729,"activeCount":99},[],{"trials":3731,"activeCount":99},[],{"trials":3733,"activeCount":99},[],{"trials":3735,"activeCount":99},[],{"intervention":3727,"totalTrials":138,"cells":3737},{"EARLY_PHASE1":3738,"PHASE1":3740,"PHASE2":3746,"PHASE3":3748,"PHASE4":3750,"NA":3752},{"trials":3739,"activeCount":99},[],{"trials":3741,"activeCount":99},[3742],{"nctId":3718,"briefTitle":3719,"status":208,"phases":3743,"primaryCompletion":3721,"completion":3722,"start":3723,"enrollment":2043,"conditions":3744,"interventions":3745},[87],[3725,278],[3711,3727],{"trials":3747,"activeCount":99},[],{"trials":3749,"activeCount":99},[],{"trials":3751,"activeCount":99},[],{"trials":3753,"activeCount":99},[],{"intervention":3755,"totalTrials":138,"cells":3756},"Lapatinib and bortezomib",{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3768,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3758,"activeCount":99},[],{"trials":3760,"activeCount":99},[3761],{"nctId":3762,"briefTitle":3763,"status":107,"phases":3764,"primaryCompletion":2082,"completion":2082,"start":1336,"enrollment":3765,"conditions":3766,"interventions":3767},"NCT01497626","Lapatinib and Bortezomib in Patients With Advanced Malignancies",[87],15,[3700],[3755],{"trials":3769,"activeCount":99},[],{"trials":3771,"activeCount":99},[],{"trials":3773,"activeCount":99},[],{"trials":3775,"activeCount":99},[],{"intervention":3777,"totalTrials":138,"cells":3778},"CS-7017 and Bexarotene",{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3792,"PHASE3":3794,"PHASE4":3796,"NA":3798},{"trials":3780,"activeCount":99},[],{"trials":3782,"activeCount":99},[3783],{"nctId":3784,"briefTitle":3785,"status":107,"phases":3786,"primaryCompletion":2654,"completion":2654,"start":1337,"enrollment":244,"conditions":3787,"interventions":3791},"NCT01504490","Phase I Study of CS-7017 and Bexarotene",[87],[3788,3789,3790],"Solid Tumors","Lymphoma","Multiple Myeloma",[3777],{"trials":3793,"activeCount":99},[],{"trials":3795,"activeCount":99},[],{"trials":3797,"activeCount":99},[],{"trials":3799,"activeCount":99},[],{"intervention":3801,"totalTrials":138,"cells":3802},"Lenalidomide, Ibrutinib, Rituximab",{"EARLY_PHASE1":3803,"PHASE1":3805,"PHASE2":3816,"PHASE3":3818,"PHASE4":3820,"NA":3822},{"trials":3804,"activeCount":99},[],{"trials":3806,"activeCount":99},[3807],{"nctId":3808,"briefTitle":3809,"status":107,"phases":3810,"primaryCompletion":3811,"completion":3812,"start":3813,"enrollment":30,"conditions":3814,"interventions":3815},"NCT02200848","Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed\u002FRefractory Chronic Lymphocytic Leukemia (CLL)",[87],"2017-03-27","2017-08-01","2014-04",[32,3197],[3801],{"trials":3817,"activeCount":99},[],{"trials":3819,"activeCount":99},[],{"trials":3821,"activeCount":99},[],{"trials":3823,"activeCount":99},[],{"intervention":420,"totalTrials":138,"cells":3825},{"EARLY_PHASE1":3826,"PHASE1":3828,"PHASE2":3834,"PHASE3":3836,"PHASE4":3838,"NA":3840},{"trials":3827,"activeCount":99},[],{"trials":3829,"activeCount":99},[3830],{"nctId":414,"briefTitle":415,"status":388,"phases":3831,"primaryCompletion":74,"completion":74,"start":417,"enrollment":99,"conditions":3832,"interventions":3833},[87],[34],[357,358,420,421],{"trials":3835,"activeCount":99},[],{"trials":3837,"activeCount":99},[],{"trials":3839,"activeCount":99},[],{"trials":3841,"activeCount":99},[],{"intervention":421,"totalTrials":138,"cells":3843},{"EARLY_PHASE1":3844,"PHASE1":3846,"PHASE2":3852,"PHASE3":3854,"PHASE4":3856,"NA":3858},{"trials":3845,"activeCount":99},[],{"trials":3847,"activeCount":99},[3848],{"nctId":414,"briefTitle":415,"status":388,"phases":3849,"primaryCompletion":74,"completion":74,"start":417,"enrollment":99,"conditions":3850,"interventions":3851},[87],[34],[357,358,420,421],{"trials":3853,"activeCount":99},[],{"trials":3855,"activeCount":99},[],{"trials":3857,"activeCount":99},[],{"trials":3859,"activeCount":99},[],{"intervention":3861,"totalTrials":138,"cells":3862},"BB-12 supplemented strawberry yogurt",{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3876,"PHASE3":3878,"PHASE4":3880,"NA":3882},{"trials":3864,"activeCount":99},[],{"trials":3866,"activeCount":99},[3867],{"nctId":3868,"briefTitle":3869,"status":208,"phases":3870,"primaryCompletion":1604,"completion":1604,"start":3871,"enrollment":3872,"conditions":3873,"interventions":3875},"NCT01652287","Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children",[87],"2013-02",62,[3874],"Children",[3861],{"trials":3877,"activeCount":99},[],{"trials":3879,"activeCount":99},[],{"trials":3881,"activeCount":99},[],{"trials":3883,"activeCount":99},[],{"intervention":3885,"totalTrials":138,"cells":3886},"cetuximab and lapatinib",{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3898,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3888,"activeCount":99},[],{"trials":3890,"activeCount":99},[3891],{"nctId":3892,"briefTitle":3893,"status":208,"phases":3894,"primaryCompletion":1901,"completion":1606,"start":1256,"enrollment":276,"conditions":3895,"interventions":3897},"NCT01184482","Lapatinib and Cetuximab in Patients With Solid Tumors",[87],[24,26,3896],"Head and Neck Cancer",[3885],{"trials":3899,"activeCount":99},[],{"trials":3901,"activeCount":99},[],{"trials":3903,"activeCount":99},[],{"trials":3905,"activeCount":99},[],{"intervention":3907,"totalTrials":138,"cells":3908},"bendamustine and lenalidomide",{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3924,"PHASE3":3926,"PHASE4":3928,"NA":3930},{"trials":3910,"activeCount":99},[],{"trials":3912,"activeCount":99},[3913],{"nctId":3914,"briefTitle":3915,"status":208,"phases":3916,"primaryCompletion":1117,"completion":1117,"start":3917,"enrollment":16,"conditions":3918,"interventions":3920},"NCT00864942","Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)",[87],"2009-02",[32,3919],"Non-Hodgkin's Lymphoma",[3907,3921,3922,3923],"BL-NHL","BLR-CLL","BLR-NHL",{"trials":3925,"activeCount":99},[],{"trials":3927,"activeCount":99},[],{"trials":3929,"activeCount":99},[],{"trials":3931,"activeCount":99},[],{"intervention":3921,"totalTrials":138,"cells":3933},{"EARLY_PHASE1":3934,"PHASE1":3936,"PHASE2":3942,"PHASE3":3944,"PHASE4":3946,"NA":3948},{"trials":3935,"activeCount":99},[],{"trials":3937,"activeCount":99},[3938],{"nctId":3914,"briefTitle":3915,"status":208,"phases":3939,"primaryCompletion":1117,"completion":1117,"start":3917,"enrollment":16,"conditions":3940,"interventions":3941},[87],[32,3919],[3907,3921,3922,3923],{"trials":3943,"activeCount":99},[],{"trials":3945,"activeCount":99},[],{"trials":3947,"activeCount":99},[],{"trials":3949,"activeCount":99},[],{"intervention":3922,"totalTrials":138,"cells":3951},{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3960,"PHASE3":3962,"PHASE4":3964,"NA":3966},{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[3956],{"nctId":3914,"briefTitle":3915,"status":208,"phases":3957,"primaryCompletion":1117,"completion":1117,"start":3917,"enrollment":16,"conditions":3958,"interventions":3959},[87],[32,3919],[3907,3921,3922,3923],{"trials":3961,"activeCount":99},[],{"trials":3963,"activeCount":99},[],{"trials":3965,"activeCount":99},[],{"trials":3967,"activeCount":99},[],{"intervention":3923,"totalTrials":138,"cells":3969},{"EARLY_PHASE1":3970,"PHASE1":3972,"PHASE2":3978,"PHASE3":3980,"PHASE4":3982,"NA":3984},{"trials":3971,"activeCount":99},[],{"trials":3973,"activeCount":99},[3974],{"nctId":3914,"briefTitle":3915,"status":208,"phases":3975,"primaryCompletion":1117,"completion":1117,"start":3917,"enrollment":16,"conditions":3976,"interventions":3977},[87],[32,3919],[3907,3921,3922,3923],{"trials":3979,"activeCount":99},[],{"trials":3981,"activeCount":99},[],{"trials":3983,"activeCount":99},[],{"trials":3985,"activeCount":99},[],{"intervention":2050,"totalTrials":138,"cells":3987},{"EARLY_PHASE1":3988,"PHASE1":3990,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3989,"activeCount":99},[],{"trials":3991,"activeCount":99},[3992],{"nctId":2037,"briefTitle":2038,"status":208,"phases":3993,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":3994,"interventions":3995},[87],[2045,2046,2047],[2030,2049,2050],{"trials":3997,"activeCount":99},[],{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[],{"trials":4003,"activeCount":99},[],{"intervention":4005,"totalTrials":138,"cells":4006},"Intravenous Artesunate",{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4017,"PHASE3":4019,"PHASE4":4021,"NA":4023},{"trials":4008,"activeCount":99},[],{"trials":4010,"activeCount":99},[4011],{"nctId":4012,"briefTitle":4013,"status":208,"phases":4014,"primaryCompletion":2082,"completion":2082,"start":1200,"enrollment":2043,"conditions":4015,"interventions":4016},"NCT02353026","Phase I Study of Intravenous Artesunate for Solid Tumors",[87],[3788],[4005],{"trials":4018,"activeCount":99},[],{"trials":4020,"activeCount":99},[],{"trials":4022,"activeCount":99},[],{"trials":4024,"activeCount":99},[],{"intervention":4026,"totalTrials":138,"cells":4027},"epirubicin hydrochloride",{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4040,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4029,"activeCount":99},[],{"trials":4031,"activeCount":99},[4032],{"nctId":4033,"briefTitle":4034,"status":208,"phases":4035,"primaryCompletion":1157,"completion":1157,"start":4036,"conditions":4037,"interventions":4038},"NCT00020748","Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer",[87],"2000-08",[3220],[4026,4039],"irinotecan hydrochloride",{"trials":4041,"activeCount":99},[],{"trials":4043,"activeCount":99},[],{"trials":4045,"activeCount":99},[],{"trials":4047,"activeCount":99},[],{"intervention":4039,"totalTrials":138,"cells":4049},{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4058,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4051,"activeCount":99},[],{"trials":4053,"activeCount":99},[4054],{"nctId":4033,"briefTitle":4034,"status":208,"phases":4055,"primaryCompletion":1157,"completion":1157,"start":4036,"conditions":4056,"interventions":4057},[87],[3220],[4026,4039],{"trials":4059,"activeCount":99},[],{"trials":4061,"activeCount":99},[],{"trials":4063,"activeCount":99},[],{"trials":4065,"activeCount":99},[],{"intervention":4067,"totalTrials":138,"cells":4068},"Nilotinib + Cetuximab",{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4079,"PHASE3":4081,"PHASE4":4083,"NA":4085},{"trials":4070,"activeCount":99},[],{"trials":4072,"activeCount":99},[4073],{"nctId":4074,"briefTitle":4075,"status":107,"phases":4076,"primaryCompletion":2654,"completion":2654,"start":1432,"enrollment":3765,"conditions":4077,"interventions":4078},"NCT01871311","A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors",[87],[24,3896],[4067],{"trials":4080,"activeCount":99},[],{"trials":4082,"activeCount":99},[],{"trials":4084,"activeCount":99},[],{"trials":4086,"activeCount":99},[],{"intervention":4088,"totalTrials":162,"cells":4089},"Amoxicillin-Clavulanate 875 Mg-125 Mg Oral",{"EARLY_PHASE1":4090,"PHASE1":4111,"PHASE2":4113,"PHASE3":4115,"PHASE4":4117,"NA":4119},{"trials":4091,"activeCount":99},[4092,4102],{"nctId":4093,"briefTitle":4094,"status":208,"phases":4095,"primaryCompletion":4096,"completion":4096,"start":4097,"enrollment":4098,"conditions":4099,"interventions":4100},"NCT03755765","Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics",[86],"2020-01-08","2019-07-23",66,[3477],[4088,4101],"BB-12",{"nctId":4103,"briefTitle":4104,"status":208,"phases":4105,"primaryCompletion":4106,"completion":4106,"start":4107,"enrollment":4108,"conditions":4109,"interventions":4110},"NCT04414722","Mechanisms of Probiotics and Antibiotic-Associated Diarrhea",[86],"2023-05-01","2021-01-01",118,[3477],[4088,4101],{"trials":4112,"activeCount":99},[],{"trials":4114,"activeCount":99},[],{"trials":4116,"activeCount":99},[],{"trials":4118,"activeCount":99},[],{"trials":4120,"activeCount":99},[],{"intervention":4101,"totalTrials":162,"cells":4122},{"EARLY_PHASE1":4123,"PHASE1":4133,"PHASE2":4135,"PHASE3":4137,"PHASE4":4139,"NA":4141},{"trials":4124,"activeCount":99},[4125,4129],{"nctId":4093,"briefTitle":4094,"status":208,"phases":4126,"primaryCompletion":4096,"completion":4096,"start":4097,"enrollment":4098,"conditions":4127,"interventions":4128},[86],[3477],[4088,4101],{"nctId":4103,"briefTitle":4104,"status":208,"phases":4130,"primaryCompletion":4106,"completion":4106,"start":4107,"enrollment":4108,"conditions":4131,"interventions":4132},[86],[3477],[4088,4101],{"trials":4134,"activeCount":99},[],{"trials":4136,"activeCount":99},[],{"trials":4138,"activeCount":99},[],{"trials":4140,"activeCount":99},[],{"trials":4142,"activeCount":99},[],{"intervention":4144,"totalTrials":138,"cells":4145},"Administration of stable Isotope labeled levothyroxine",{"EARLY_PHASE1":4146,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4165,"NA":4167},{"trials":4147,"activeCount":99},[4148],{"nctId":4149,"briefTitle":4150,"status":208,"phases":4151,"primaryCompletion":4152,"completion":4153,"start":4154,"enrollment":4155,"conditions":4156,"interventions":4158},"NCT03102177","Effect of Age, Weight and Sex on Levothyroxine Pharmacokinetics",[86],"2013-11-30","2016-07-26","2011-05-31",41,[4157],"Hypothyroidism Primary",[4144],{"trials":4160,"activeCount":99},[],{"trials":4162,"activeCount":99},[],{"trials":4164,"activeCount":99},[],{"trials":4166,"activeCount":99},[],{"trials":4168,"activeCount":99},[],{"intervention":396,"totalTrials":366,"cells":4170},{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4175,"PHASE3":4189,"PHASE4":4191,"NA":4193},{"trials":4172,"activeCount":99},[],{"trials":4174,"activeCount":99},[],{"trials":4176,"activeCount":99},[4177,4181],{"nctId":386,"briefTitle":387,"status":388,"phases":4178,"primaryCompletion":390,"completion":390,"start":391,"enrollment":99,"conditions":4179,"interventions":4180},[88],[393,394],[126,384,357,396],{"nctId":4182,"briefTitle":4183,"status":388,"phases":4184,"primaryCompletion":3053,"completion":1901,"start":4185,"enrollment":99,"conditions":4186,"interventions":4187},"NCT00881114","Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer",[88],"2009-04",[3896],[396,4188],"Cetuximab",{"trials":4190,"activeCount":99},[],{"trials":4192,"activeCount":99},[],{"trials":4194,"activeCount":99},[4195],{"nctId":4196,"briefTitle":4197,"status":107,"phases":4198,"primaryCompletion":2655,"completion":1901,"start":4199,"enrollment":162,"conditions":4200,"interventions":4202},"NCT01790516","Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer",[91],"2012-05",[4201],"Head and Neck Squamous Cell Cancer",[396,4203],"cetuximab",{"intervention":4203,"totalTrials":162,"cells":4205},{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4216,"PHASE4":4218,"NA":4220},{"trials":4207,"activeCount":99},[],{"trials":4209,"activeCount":99},[],{"trials":4211,"activeCount":99},[4212],{"nctId":4182,"briefTitle":4183,"status":388,"phases":4213,"primaryCompletion":3053,"completion":1901,"start":4185,"enrollment":99,"conditions":4214,"interventions":4215},[88],[3896],[396,4188],{"trials":4217,"activeCount":99},[],{"trials":4219,"activeCount":99},[],{"trials":4221,"activeCount":99},[4222],{"nctId":4196,"briefTitle":4197,"status":107,"phases":4223,"primaryCompletion":2655,"completion":1901,"start":4199,"enrollment":162,"conditions":4224,"interventions":4225},[91],[4201],[396,4203],{"intervention":1941,"totalTrials":162,"cells":4227},{"EARLY_PHASE1":4228,"PHASE1":4230,"PHASE2":4232,"PHASE3":4238,"PHASE4":4240,"NA":4242},{"trials":4229,"activeCount":99},[],{"trials":4231,"activeCount":99},[],{"trials":4233,"activeCount":99},[4234],{"nctId":1934,"briefTitle":1935,"status":107,"phases":4235,"primaryCompletion":1937,"completion":1937,"start":1938,"enrollment":276,"conditions":4236,"interventions":4237},[88],[15],[1914,1941,1942],{"trials":4239,"activeCount":99},[],{"trials":4241,"activeCount":99},[],{"trials":4243,"activeCount":99},[4244],{"nctId":4245,"briefTitle":4246,"status":107,"phases":4247,"primaryCompletion":2930,"completion":4248,"start":4249,"enrollment":4250,"conditions":4251,"interventions":4252},"NCT00898937","Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast",[],"2017-07","1999-09",55,[15],[1941],{"intervention":4254,"totalTrials":138,"cells":4255},"1% phenylephrine and 0.2% cyclopentolate",{"EARLY_PHASE1":4256,"PHASE1":4258,"PHASE2":4260,"PHASE3":4262,"PHASE4":4264,"NA":4266},{"trials":4257,"activeCount":99},[],{"trials":4259,"activeCount":99},[],{"trials":4261,"activeCount":99},[],{"trials":4263,"activeCount":99},[],{"trials":4265,"activeCount":99},[],{"trials":4267,"activeCount":99},[4268],{"nctId":4269,"briefTitle":4270,"status":208,"phases":4271,"primaryCompletion":2592,"completion":4272,"start":4273,"enrollment":3765,"conditions":4274,"interventions":4276},"NCT01054027","Study on Effective Mydriasis in Premature Infants",[91],"2008-03","2007-03",[4275],"Retinopathy of Prematurity (ROP)",[4254],{"intervention":4278,"totalTrials":138,"cells":4279},"cyanocobalamin",{"EARLY_PHASE1":4280,"PHASE1":4282,"PHASE2":4284,"PHASE3":4286,"PHASE4":4288,"NA":4290},{"trials":4281,"activeCount":99},[],{"trials":4283,"activeCount":99},[],{"trials":4285,"activeCount":99},[],{"trials":4287,"activeCount":99},[],{"trials":4289,"activeCount":99},[],{"trials":4291,"activeCount":99},[4292],{"nctId":4293,"briefTitle":4294,"status":208,"phases":4295,"completion":4296,"start":4297,"enrollment":4298,"conditions":4299,"interventions":4302},"NCT00004495","Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis",[91],"2000-09","1999-06",84,[4300,4301],"End Stage Renal Disease","Hyperhomocysteinemia",[4278,4303,4304],"folic acid","pyridoxine",{"intervention":4303,"totalTrials":138,"cells":4306},{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4311,"PHASE3":4313,"PHASE4":4315,"NA":4317},{"trials":4308,"activeCount":99},[],{"trials":4310,"activeCount":99},[],{"trials":4312,"activeCount":99},[],{"trials":4314,"activeCount":99},[],{"trials":4316,"activeCount":99},[],{"trials":4318,"activeCount":99},[4319],{"nctId":4293,"briefTitle":4294,"status":208,"phases":4320,"completion":4296,"start":4297,"enrollment":4298,"conditions":4321,"interventions":4322},[91],[4300,4301],[4278,4303,4304],{"intervention":4304,"totalTrials":138,"cells":4324},{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4329,"PHASE3":4331,"PHASE4":4333,"NA":4335},{"trials":4326,"activeCount":99},[],{"trials":4328,"activeCount":99},[],{"trials":4330,"activeCount":99},[],{"trials":4332,"activeCount":99},[],{"trials":4334,"activeCount":99},[],{"trials":4336,"activeCount":99},[4337],{"nctId":4293,"briefTitle":4294,"status":208,"phases":4338,"completion":4296,"start":4297,"enrollment":4298,"conditions":4339,"interventions":4340},[91],[4300,4301],[4278,4303,4304],{"intervention":4342,"totalTrials":138,"cells":4343},"Privigen",{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4348,"PHASE3":4350,"PHASE4":4352,"NA":4354},{"trials":4345,"activeCount":99},[],{"trials":4347,"activeCount":99},[],{"trials":4349,"activeCount":99},[],{"trials":4351,"activeCount":99},[],{"trials":4353,"activeCount":99},[],{"trials":4355,"activeCount":99},[4356],{"nctId":4357,"briefTitle":4358,"status":283,"phases":4359,"primaryCompletion":4360,"completion":4361,"start":4362,"enrollment":199,"conditions":4363,"interventions":4366},"NCT01785056","IVIG Treatment in Systemic Sclerosis",[91],"2018-01","2019-01","2013-04",[4364,4365],"Systemic Sclerosis","Diffuse Scleroderma",[4342],{"intervention":4368,"totalTrials":138,"cells":4369},"Buprenorphine",{"EARLY_PHASE1":4370,"PHASE1":4372,"PHASE2":4374,"PHASE3":4376,"PHASE4":4378,"NA":4380},{"trials":4371,"activeCount":99},[],{"trials":4373,"activeCount":99},[],{"trials":4375,"activeCount":99},[],{"trials":4377,"activeCount":99},[],{"trials":4379,"activeCount":99},[],{"trials":4381,"activeCount":99},[4382],{"nctId":4383,"briefTitle":4384,"status":107,"phases":4385,"primaryCompletion":4386,"completion":4386,"start":2381,"enrollment":3765,"conditions":4387,"interventions":4388},"NCT03063905","The Effects of Opioid Taper on Opioid-Induced Hyperalgesia",[],"2018-02-28",[4368,346],[4368],{"intervention":4390,"totalTrials":138,"cells":4391},"western blotting",{"EARLY_PHASE1":4392,"PHASE1":4394,"PHASE2":4396,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4393,"activeCount":99},[],{"trials":4395,"activeCount":99},[],{"trials":4397,"activeCount":99},[],{"trials":4399,"activeCount":99},[],{"trials":4401,"activeCount":99},[],{"trials":4403,"activeCount":99},[4404],{"nctId":4405,"briefTitle":4406,"status":388,"phases":4407,"start":4408,"enrollment":99,"conditions":4409,"interventions":4410},"NCT01012804","Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer",[],"2000-01",[24],[4390],{"intervention":4412,"totalTrials":138,"cells":4413},"Fenoldopam",{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4418,"PHASE3":4420,"PHASE4":4422,"NA":4424},{"trials":4415,"activeCount":99},[],{"trials":4417,"activeCount":99},[],{"trials":4419,"activeCount":99},[],{"trials":4421,"activeCount":99},[],{"trials":4423,"activeCount":99},[],{"trials":4425,"activeCount":99},[4426],{"nctId":4427,"briefTitle":4428,"status":208,"phases":4429,"primaryCompletion":4430,"completion":4431,"start":4432,"enrollment":213,"conditions":4433,"interventions":4435},"NCT01324245","Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet",[91],"2005-12","2006-05","2002-11",[4434],"Salt-sensitive Hypertension",[4412],{"intervention":4437,"totalTrials":138,"cells":4438},"1% lidocaine",{"EARLY_PHASE1":4439,"PHASE1":4441,"PHASE2":4443,"PHASE3":4445,"PHASE4":4447,"NA":4449},{"trials":4440,"activeCount":99},[],{"trials":4442,"activeCount":99},[],{"trials":4444,"activeCount":99},[],{"trials":4446,"activeCount":99},[],{"trials":4448,"activeCount":99},[],{"trials":4450,"activeCount":99},[4451],{"nctId":4452,"briefTitle":4453,"status":107,"phases":4454,"primaryCompletion":1604,"completion":1604,"start":4455,"enrollment":30,"conditions":4456,"interventions":4458},"NCT01606150","Lumbar Punctures in Neonates: Improving Success Rates and Minimizing Pain",[91],"2012-11",[4457],"Meningitis",[4437,4459],"topical lidocaine",{"intervention":4459,"totalTrials":138,"cells":4461},{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4468,"PHASE4":4470,"NA":4472},{"trials":4463,"activeCount":99},[],{"trials":4465,"activeCount":99},[],{"trials":4467,"activeCount":99},[],{"trials":4469,"activeCount":99},[],{"trials":4471,"activeCount":99},[],{"trials":4473,"activeCount":99},[4474],{"nctId":4452,"briefTitle":4453,"status":107,"phases":4475,"primaryCompletion":1604,"completion":1604,"start":4455,"enrollment":30,"conditions":4476,"interventions":4477},[91],[4457],[4437,4459],{"intervention":4479,"totalTrials":138,"cells":4480},"ENVARSUS®",{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4485,"PHASE3":4487,"PHASE4":4489,"NA":4491},{"trials":4482,"activeCount":99},[],{"trials":4484,"activeCount":99},[],{"trials":4486,"activeCount":99},[],{"trials":4488,"activeCount":99},[],{"trials":4490,"activeCount":99},[],{"trials":4492,"activeCount":99},[4493],{"nctId":4494,"briefTitle":4495,"status":107,"phases":4496,"primaryCompletion":4497,"completion":4497,"start":1837,"enrollment":9,"conditions":4498,"interventions":4500},"NCT02956005","Envarsus XR in African American Renal Transplant Recipients",[91],"2018-09",[4499],"Renal Transplant Recipients",[4479],{"intervention":4502,"totalTrials":138,"cells":4503},"cyclosporin and methotrexate",{"EARLY_PHASE1":4504,"PHASE1":4506,"PHASE2":4508,"PHASE3":4510,"PHASE4":4512,"NA":4514},{"trials":4505,"activeCount":99},[],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"trials":4511,"activeCount":99},[],{"trials":4513,"activeCount":99},[],{"trials":4515,"activeCount":99},[4516],{"nctId":4517,"briefTitle":4518,"status":208,"phases":4519,"primaryCompletion":4520,"completion":4520,"start":4521,"enrollment":19,"conditions":4522,"interventions":4524},"NCT00905073","Low Dose Cyclosporin and Methotrexate Therapy in Diabetes",[91],"1994-06","1990-02",[4523],"Type 1 Diabetes Mellitus",[4502],{"intervention":4526,"totalTrials":138,"cells":4527},"Modified FOLFOX6",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4532,"PHASE3":4534,"PHASE4":4536,"NA":4538},{"trials":4529,"activeCount":99},[],{"trials":4531,"activeCount":99},[],{"trials":4533,"activeCount":99},[],{"trials":4535,"activeCount":99},[],{"trials":4537,"activeCount":99},[],{"trials":4539,"activeCount":99},[4540],{"nctId":4541,"briefTitle":4542,"status":107,"phases":4543,"primaryCompletion":2885,"completion":2885,"start":3260,"enrollment":4544,"conditions":4545,"interventions":4546},"NCT02358863","Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach",[91],13,[3309,3310],[4526,4547,4548,4549,4550,4551,4552,4553],"Docetaxel\u002FCapecitabine","Cisplatin\u002FIrinotecan","Cisplatin\u002FDocetaxel","IRI\u002FEPI","EPI\u002FDocetaxel","Irinotecan\u002FDocetaxel","Docetaxel",{"intervention":4547,"totalTrials":138,"cells":4555},{"EARLY_PHASE1":4556,"PHASE1":4558,"PHASE2":4560,"PHASE3":4562,"PHASE4":4564,"NA":4566},{"trials":4557,"activeCount":99},[],{"trials":4559,"activeCount":99},[],{"trials":4561,"activeCount":99},[],{"trials":4563,"activeCount":99},[],{"trials":4565,"activeCount":99},[],{"trials":4567,"activeCount":99},[4568],{"nctId":4541,"briefTitle":4542,"status":107,"phases":4569,"primaryCompletion":2885,"completion":2885,"start":3260,"enrollment":4544,"conditions":4570,"interventions":4571},[91],[3309,3310],[4526,4547,4548,4549,4550,4551,4552,4553],{"intervention":4548,"totalTrials":138,"cells":4573},{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4578,"PHASE3":4580,"PHASE4":4582,"NA":4584},{"trials":4575,"activeCount":99},[],{"trials":4577,"activeCount":99},[],{"trials":4579,"activeCount":99},[],{"trials":4581,"activeCount":99},[],{"trials":4583,"activeCount":99},[],{"trials":4585,"activeCount":99},[4586],{"nctId":4541,"briefTitle":4542,"status":107,"phases":4587,"primaryCompletion":2885,"completion":2885,"start":3260,"enrollment":4544,"conditions":4588,"interventions":4589},[91],[3309,3310],[4526,4547,4548,4549,4550,4551,4552,4553],{"intervention":4549,"totalTrials":138,"cells":4591},{"EARLY_PHASE1":4592,"PHASE1":4594,"PHASE2":4596,"PHASE3":4598,"PHASE4":4600,"NA":4602},{"trials":4593,"activeCount":99},[],{"trials":4595,"activeCount":99},[],{"trials":4597,"activeCount":99},[],{"trials":4599,"activeCount":99},[],{"trials":4601,"activeCount":99},[],{"trials":4603,"activeCount":99},[4604],{"nctId":4541,"briefTitle":4542,"status":107,"phases":4605,"primaryCompletion":2885,"completion":2885,"start":3260,"enrollment":4544,"conditions":4606,"interventions":4607},[91],[3309,3310],[4526,4547,4548,4549,4550,4551,4552,4553],{"intervention":4550,"totalTrials":138,"cells":4609},{"EARLY_PHASE1":4610,"PHASE1":4612,"PHASE2":4614,"PHASE3":4616,"PHASE4":4618,"NA":4620},{"trials":4611,"activeCount":99},[],{"trials":4613,"activeCount":99},[],{"trials":4615,"activeCount":99},[],{"trials":4617,"activeCount":99},[],{"trials":4619,"activeCount":99},[],{"trials":4621,"activeCount":99},[4622],{"nctId":4541,"briefTitle":4542,"status":107,"phases":4623,"primaryCompletion":2885,"completion":2885,"start":3260,"enrollment":4544,"conditions":4624,"interventions":4625},[91],[3309,3310],[4526,4547,4548,4549,4550,4551,4552,4553],{"intervention":4551,"totalTrials":138,"cells":4627},{"EARLY_PHASE1":4628,"PHASE1":4630,"PHASE2":4632,"PHASE3":4634,"PHASE4":4636,"NA":4638},{"trials":4629,"activeCount":99},[],{"trials":4631,"activeCount":99},[],{"trials":4633,"activeCount":99},[],{"trials":4635,"activeCount":99},[],{"trials":4637,"activeCount":99},[],{"trials":4639,"activeCount":99},[4640],{"nctId":4541,"briefTitle":4542,"status":107,"phases":4641,"primaryCompletion":2885,"completion":2885,"start":3260,"enrollment":4544,"conditions":4642,"interventions":4643},[91],[3309,3310],[4526,4547,4548,4549,4550,4551,4552,4553],{"intervention":4552,"totalTrials":138,"cells":4645},{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4650,"PHASE3":4652,"PHASE4":4654,"NA":4656},{"trials":4647,"activeCount":99},[],{"trials":4649,"activeCount":99},[],{"trials":4651,"activeCount":99},[],{"trials":4653,"activeCount":99},[],{"trials":4655,"activeCount":99},[],{"trials":4657,"activeCount":99},[4658],{"nctId":4541,"briefTitle":4542,"status":107,"phases":4659,"primaryCompletion":2885,"completion":2885,"start":3260,"enrollment":4544,"conditions":4660,"interventions":4661},[91],[3309,3310],[4526,4547,4548,4549,4550,4551,4552,4553],{"intervention":4553,"totalTrials":138,"cells":4663},{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4668,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4665,"activeCount":99},[],{"trials":4667,"activeCount":99},[],{"trials":4669,"activeCount":99},[],{"trials":4671,"activeCount":99},[],{"trials":4673,"activeCount":99},[],{"trials":4675,"activeCount":99},[4676],{"nctId":4541,"briefTitle":4542,"status":107,"phases":4677,"primaryCompletion":2885,"completion":2885,"start":3260,"enrollment":4544,"conditions":4678,"interventions":4679},[91],[3309,3310],[4526,4547,4548,4549,4550,4551,4552,4553],{"intervention":4681,"totalTrials":138,"cells":4682},"Omegaven 10%",{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4689,"PHASE4":4691,"NA":4693},{"trials":4684,"activeCount":99},[],{"trials":4686,"activeCount":99},[],{"trials":4688,"activeCount":99},[],{"trials":4690,"activeCount":99},[],{"trials":4692,"activeCount":99},[],{"trials":4694,"activeCount":99},[4695],{"nctId":4696,"briefTitle":4697,"status":4698,"phases":4699,"conditions":4700,"interventions":4702},"NCT01861834","Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage","APPROVED_FOR_MARKETING",[],[4701],"Cholestasis of Parenteral Nutrition",[4681]]